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Summary 
Naturally occurring RSeS form an interesting alcove of redox biology in living cells. These 
species provide interesting information for the design and synthesis of RSeS which modulate 
the redox state of cells and further grant important insights on lead structures in the hunt for 
active agents against infectious diseases associated with Oxidative Stress (OS). 
In the present study, several synthetic RSeS were prepared and, thereafter, evaluated 
biologically against a plethora of targets. The synthetic compounds belong to different classes 
of organo-selenium compounds ranging from simple aromatic selenocyanates to ebselen-like 
selenazolinium salts and even rather complicated multi-component hybrid redox catalysts. 
These organic RSeS and some inorganic salts of selenium and tellurium were evaluated 
against a broad spectrum of microorganisms, including Gram-positive and Gram-negative 
bacteria of the notorious ESKAPE family, yeasts and multicellular nematodes. Some of the 
compounds, such as aryl methyl selenocyanates, were also investigated for cytotoxic activity 
against normal and cancer cell lines. 
Generally, all the synthetic RSeS exhibited excellent activity against the selected targets. The 
preliminary mechanistic studies revealed that such compounds interact with the cellular 
thiolstat of the target organism. The interaction of selenium-based agents with intracellular 
thiolstat sets forth novel possibilities to tailor potent, efficient and target-oriented 
multifunctional RSeS. 
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Zusammenfassung 
Natürlich vorkommende RSeS bilden eine interessante Nische der Redox-Biologie in 
lebenden Zellen. Diese Spezies liefern interessante Informationen für das Design und die 
Synthese von RSeS, die den Redox-Zustand der Zellen modulieren und wichtige Erkenntnisse 
über Leitstrukturen bei der Suche nach Wirkstoffen gegen Infektionskrankheiten im 
Zusammenhang mit Oxidativem Stress liefern. 
In der vorliegenden Arbeit wurden mehrere synthetische RSeS vorbereitet und anschließend 
gegen eine Vielzahl von biologischen Targets bewertet. Die synthetischen Verbindungen 
gehören zu verschiedenen Klassen von Organoselenverbindungen, die von einfachen 
aromatischen Selenocyanaten über ebselenartige Selenazolinium Salze bis hin zu 
komplexeren mehrkomponentige Hybrid-Redoxkatalysatoren reichen. Diese Verbindungen 
wurden anhand eines breiten Spektrums an Mikroorganismen bewertet, darunter Gram-positiv 
und Gram-negativ Bakterien der berüchtigten ESKAPE-Familie, Hefen und Nematoden. 
Einige der Verbindungen, wie beispielsweise Arylmethylselenocyanate, wurden auch auf 
zytotoxische Aktivität gegen normale und Krebs-Zell linien untersucht. 
Im Allgemeinen zeigten alle synthetischen RSeS eine ausgezeichnete Aktivität gegenüber den 
ausgewählten Zielen. Die mechanistischen Vorstudien zeigten, dass solche Verbindungen mit 
dem zellulären Thiolstat des Zielorganismus interagieren. Diese Interaktionen eröffnen neue 
Möglichkeiten, potente, effiziente und zielgerichtete multifunktionale RSeS zu gestalten. 
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1. Introduction 
1.1. The rise of the Greek moon  
Selenium was discovered in 1817 by Jöns Jacob Berzelius (1779-1848), a Swedish chemist. 
The history of the discovery of this unique element is interesting and dates back to the 
beginning of the 18
th
 century with the establishment of a chemical factory in the vicinity of 
the Castle of Gripsholm in Mariefred, Södermanland, Sweden, for the production of white 
lead paint. The production of paint involved the utilisation of acetic acid and sulfuric acid. 
The preparation of sulfuric acid involved the reaction of sulfur dioxide (by burning pyrite) 
with nitrogen dioxide in the presence of water in lead-lined chambers. The factory was soon 
liquidated due to several unfavourable conditions and was subsequently acquired by a team of 
entrepreneurs and chemists, namely Johan Gottlieb Gahn (1745-1818), Hans Peter Eggertz 
(1781-1867), and Jöns Jacob Berzelius [1,2]. The former proprietor of the chemical factory 
had observed the formation of reddish sludge in the lead chamber whenever the pyrite from 
Falun (Sweden) was utilized as a source of sulfur for the preparation of sulfuric acid. The 
reddish sludge was assumed to be an arsenic compound which was considered toxic and 
dangerous, so the utilization of pyrite from Falun was discontinued. The new owners Gahn 
and Eggertz insisted on utilizing the pyrite from Falun for the production of sulfuric acid. The 
reddish sludge was subsequently investigated by Gahn and Berzelius. The initial chemical 
analysis revealed the possibility of presence of tellurium also. Berzelius pursued his surprising 
investigations and reached a conclusion that the sludge must also contain a novel element. He 
named this element as “Selenium” (Greek: selḗnē, moon) which was chosen due to its 
similarity with tellurium (Latin: tellus, earth ) which had been discovered a couple of decades 
earlier, in 1783, by the Austrian chemist Franz-Joseph Müller von Reichenstein (1740-1826) 
[3,4]. It is curious to note that Jöns Jacob Berzelius referred to the Greek, and not Latin name, 
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despite the fact that “tellus” was in essence a “latino”, otherwise he may have named the 
element as “lunatium” and this thesis would then address quite a few lunatic issues 
concerning “Reactive Lunatic Species”. The name was mentioned as: 
“skola beskrifvas vara en egen förut okänd brännbar mineralkropp, hvilken jag har kallat 
Selenium af ∑εληνη, måna, för at dermed utmerka dess nära slägtskap med Tellurium“ [2]. 
1.2. Selenium: a “sensitive” element 
Since its discovery, selenium has attracted the attention of numerous scientists who, later on, 
employed it in various areas of Science. Willoughby Smith (1828-1891) was the first one who 
discovered the photo-sensitive nature of elemental selenium in 1873 [5]. The famous German 
inventor Werner von Siemens (1816-1892) designed the first semiconductor based on 
selenium in construction in 1875 which was subsequently employed by Alexander Graham 
Bell (1847-1922) in the invention of the famous photo phone in 1880 which used to employ 
light for the transmission of sound [6,7]. The sequence of discoveries continued with the 
development of selenium cells by Charles Fritts (1850-1903) in 1884 which served as 
exposure meter for photographic instruments for several years [8,9].The photosensitive nature 
of selenium was employed to design solar panels and first solar arrays was installed by 
Charles Fritts on a New York city rooftop in 1884 [8,10]. Another interesting application of 
elemental selenium was established in the field of photography. The sensitive nature of 
selenium continued attracting scientists from various areas of Science and Industry. In fact, 
the element was discovered by a chemist, and explored by various physicists who channelled 
the sensitivity in the development of diverse fields of science and revolutionised the world 
with innovative inventions ranging from electrical semiconductors or solar cells all the way 
towards xerography in photography and graphic reproduction [11].  
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1.3. From photo sensitivity to redox sensitivity 
The “sensitive” nature of selenium continued to lay the foundation for various other areas of 
Science. The redox-sensitive nature of selenium has recently contributed enormously to the 
field of organic synthetic chemistry. Various redox-active and also redox-modulating 
molecules based on selenium have been designed and synthesized for treating diseases 
associated with Oxidative Stress (OS). OS has been defined as “an imbalance between 
oxidants and antioxidants in the favour of oxidants, potentially leading to damage” by Helmut 
Sies in 1985 [12-14]. Organo-selenium compounds can selectively target oxidatively stressed 
cells as these cells have elevated levels of Reactive Oxygen Species (ROS) as compared to 
normal cells. The redox sensitive nature of selenium has led to the design of various classes of 
organo-selenium compounds and several lead structures have been synthesized.  
1.4. From Toxin to Therapy 
Selenium had always been considered dangerous and toxic for human consumption. The 
history of toxicity of selenium dates back to 13
th
 century when Marco Polo (1254-1324) 
observed that the hoofs of animals dropped off by the consumption of selenoferous plants in 
the mountainous region of western China although no one was aware of presence of selenium 
at that time, of course [15]. Maurice I. Smith and his colleagues reported the toxic effects of 
selenium on the health of people living on selenoferous soils in 1936 [16]. Its role as an 
essential nutrient was later recognised in animals in the 1950s and in human beings in 1973, 
in fact, with the discovery of selenium as an integral component of redox enzyme glutathione 
peroxidase [17,18]. Selenium forms an integral part of various proteins (selenoproteins) which 
play various important roles not only in growth and development. They also serve as essential 
components of antioxidant defence systems [19]. Many selenoproteins and selenoenzymes 
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contain selenocysteines (SeCys) and are mostly involved in oxidoreduction reactions which 
are extremely important for the intracellular redox homeostasis [20]. Glutathione peroxidase 1 
(GPx 1), for instance, being the first selenoprotein discovered in 1957, is a crucial antioxidant 
enzyme which eliminates ROS and protects the cell against oxidative damages [21]. The 
redox biology of this unique protein has been studied extensively in the context of oxidative 
stress-related diseases i.e. prevention and therapy for cancer, cardio and neuro protection [22]. 
Other selenoproteins contain the amino acid selenomethionine (SeMet), the prime nutritional 
representative form of selenium. Since the tRNA responsible for the incorporation does not 
discriminate between Met and SeMet, SeMet assimilates into proteins as effectively as 
methionine (Met) [23,24]. Proteins containing SeMet, in contrast to other selenoproteins, do 
not participate in cell growth and are directly metabolized by the organisms to other forms of 
selenium i.e. SeCys, dimethyl selenide and trimethyl selenonium salts [25,26]. The unique 
role of selenium as a redox modulator in these selenoproteins and enzymes has inspired 
scientists to design and synthesise selenium-based GPx mimics. These endeavours have led to 
the development of multifunctional drugs, such as ebselen (2-phenyl-1,2-benzisoselenazol-
3(2H)-one), which have been studied extensively in the context of antioxidant activity and 
cancer prevention. Ebselen is currently undergoing clinical trials in the treatment of mania 
and hypomania [27,28]. 
1.5. Reactive Selenium Species (RSeS): an emerging concept 
The concept of “Reactive Sulfur Species” (RSS) was postulated by Claus Jacob, Gregory I. 
Giles and Karen M. Tasker in 2001. It elaborates the roles of various sulfur containing 
metabolites in the context of OS [29]. Today, the analogy between sulfur and selenium 
provides grounds for postulation of the presence of similar Reactive Selenium Species 
(RSeS). Both sulfur and selenium are able to undergo redox modulation and interfere with the 
Introduction 
__________________________________________________________________________________ 
5 
 
redox-sensitive signalling proteins, thereby, interfering with the cellular thiolstat. RSS are 
more abundant still less reactive whilst RSeS are more reactive and less common. A brief 
comparison for different characteristics between sulfur and selenium atoms as well as RSS 
and RSeS is provided in Table 1.  
Table 1. Comparison of the different physical, chemical and biochemical properties of 
elemental sulfur and selenium as well as RSS and RSeS.  
Physicochemical Properties Sulfur /RSS Selenium/RSeS 
Weight light heavy 
Size 100 pm 115 pm 
Polarizability low higher 
Bond strengths strong weak 
Bond breaking reactions slower faster 
Energy level of sigma orbital higher lower 
Stability at higher oxidation state higher lower 
Acidity less acidic more acidic 
Nucleophilicity lower higher 
To act as leaving group  lower higher 
Hypervalency 
less stable (e.g. sulfuranes, 
R4S decompose at -67 °C) 
more stable (e.g. 
selenuranes, R4Se 
decompose at 0 °C) 
Electrophilicity lower higher 
π-Bonding stronger weaker 
Chemical reactivity slower faster 
Bonding with oxygen strong weak 
Dipolar character of chalcogen-oxygen bond weak strong 
Feasibility to form chalcogen oxides highly favoured less favoured 
Preference for lower oxidation state lower higher 
Nature of chalcogen dioxide  SO2 is a mild reducing agent SeO2 is a mild oxidizing 
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agent  
Oxidation of chalcogen oxides easy difficult 
Nucleophilicity of lone pair  high Low 
Redox potential  thiols have higher redox 
potentials 
selenols have lower redox 
potentials 
Rate of formation of di-chalcogenides low high 
Bond dissociation energy (BDE) of O-H and 
chalcogen-H bond in sulfenic and selenenic acids 
BDE of S-H bond (366.52 kJ 
mol
-1
) is higher than O-H 
bond (287.02 kJ mol
-1
) in 
sulfenic acid 
BDE of Se-H bond (330.12 
kJ mol
-1
) is lower than O-
H bond (339.74 kJ mol
-1
) 
in selenenic acid 
Nature of sulfinic and seleninic acids sulfinic acids are mild 
reducing agents 
seleninic acids are mild 
oxidizing agents 
Interaction of sulfinic and seleninic acids with 
thiols 
rate of reaction of thiols 
with sulfinic acids is 10
6
 
times slower as compared 
to seleninic acids acids 
rate of reaction of thiols 
with seleninic acids is 10
6
 
times faster as compared 
to sulfinic acids 
Reduction of sulfinic/seleninic acids to the 
oxidation states of 0 and -2 
slow fast 
One electron redox reactions faster slower 
Catalysis for enzyme less. Cysteine is less catalytic 
than selenocysteine 
more. Selenocysteine is 
more catalytic than 
cysteine 
The term RSeS has been chosen to highlight the redox modulating, mostly oxidizing nature of 
certain organo-selenium compounds [30]. In comparison to the concept of RSS, the concept 
of RSeS is rather new and evolving. RSeS primarily include simple naturally occurring 
selenium-containing molecules, such as selenium nanoparticles, hydrogen selenide, 
selenocysteine, selenomethioneine and selenoneine. Nonetheless the term RSeS is quite broad 
and could also include several synthetic organo-selenium compounds, such as ebselen, 
selenocyanates, selenazolinium salts and selenium-based redox catalysts. The biochemical 
analogy comes from the fact that RSeS interfere with the cysteine (Cys) residues of the 
cellular thiolstat and trigger cellular signalling pathways which may either lead towards the 
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activation of antioxidant response or apoptosis just as often observed in the case of RSS. The 
presence of selenium donates more oxidizing or even catalytic characteristics to RSeS and 
therefore, these species, are often biologically active and, for instance, destroy certain target 
cancer cells effectively and selectively. The concepts of RSS and RSeS also provide a strong 
basis for the design and development of target based organo-selenium compounds (Figure 1).  
 
Figure 1. The figure provides an insight how the concepts of reactive sulfur and selenium 
species could be exploited in the development of innovative drug molecules. Some of these 
avenues are explored as part of this thesis. 
The concept of RSeS is not only confined to naturally occurring organo-selenium agents e.g. 
elemental selenium (Se
0
), hydrogen selenide (H2Se), selenocysteine, selenomethionine and 
selenoneine, rather it also includes synthetic compounds inspired from nature e.g. 
selenocyanates and redox modulating hybrid-molecules e.g. seleno-quinones and seleno-
lapachones.  
1.5.1. Selenocysteine 
Among the various RSeS, certain molecules are abundantly dispersed in nature and some of 
them are even considered as essential amino acids, such as selenocysteine (SeCys) which is 
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the selenium analogue of cysteine. SeCys is one of the most important RSeS which is 
incorporated into proteins following a certain specific mechanism which involves 
contributions from the DNA, a specific selenocystein insertion sequence (SECIS) and tRNA 
[31,32]. The redox chemistry of SeCys is associated with the selenenol/selenolate group. 
SeCys consumes thiols and converts peroxides (ROS) to alcohols and water catalytically, 
thereby protecting cells from oxidative damages [33]. The peroxidase cycles of SeCys and 
Cys involve the nucleophilic interaction of selenolate / thiolate with the oxidant (such as 
H2O2) to generate selenenic/ sulfenic acid which subsequently reacts with cellular thiols to 
produce mixed selenosulfide/disulfide. The interaction of these mixed selenosulfides or 
disulfides with further thiols regenerates the active enzyme (Figure 2). An interesting 
difference between the two peroxidases is the high reactivity of selenium compared to sulfur 
which enables the over-oxidized form of SeCys peroxidase (SeCys-Se(O)O
-
) to oxidize 
exogenous thiols and return back to the catalytic cycle (Figure 2). In contrast, the over-
oxidized form of cysteine peroxidase (Cys-S(O)O
-
) is unable to oxidize the exogenous thiols 
and sulfinic acid formation (Cys-S(O)OH) therefore often leads to “self-inactivation”. 
Peroxiredoxin (Prdx) is an exception as it can count on a special repair enzyme to reduce the 
over-oxidized form of Cys peroxidase and bring it back to the normal catalytic cycle [34]. 
This catalytic removal of peroxide leads to the antioxidant mechanism which is also employed 
by several other selenoenzymes, such as glutathione peroxidase (GPx) and even some organo-
selenium compounds, such as ebselen, for instance, which in certain respects mimic the 
catalytic cycle of GPx.  
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Figure 2. Comparison of the peroxidase cycles of (a) SeCys and (b) Cys commonly employed 
by enzymes such as GPx and Prdx, respectively. Isosteric replacement of sulfur for selenium 
plays a crucial role and enhances the peroxidase activity considerably.  
1.5.2. Selenomethionine 
Selenomethionine (SeMet) is also an interesting naturally occurring amino acid which can be 
integrated easily into cellular proteins and enzymes. It has been reported that SeMet constitute 
20% and SeCys constitute 80% of the selenoproteins in human serum [35]. In contrast to 
animal kingdom, SeMet is the major form of selenium found in plants as it has been observed 
that tRNA responsible for the incorporation of methionine (Met) to the proteins does not 
discriminate between the sulfur and the selenium analogues. Although SeMet is not essential 
for the growth and development of plants, it is synthesized along with Met in quantities 
depending upon the amount of selenium available [36,37]. Intriguingly, a very high content of 
SeMet (ranging from 81-82%) was observed in some plants, such as seleniferous corn, wheat 
and soybeans [38]. Moreover, backer’s yeast Saccharomyces cerevisiae, which is able to 
assimilate up to 3 mg/g of Se, incorporates more than 90 % of the total Se in the form of 
SeMet [39-41]. SeMet protects proteins and enzymes by providing an additional selenium-
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based “antioxidant shield”. The redox chemistry of SeMet is rather interesting, as it combines 
the redox chemistry of selenides, selenoxides and selenones as depicted in Figure 3.  
 
Figure 3. Selenium imparts strong antioxidant activity to SeMet. The oxidation of SeMet 
leads to the formation of selenoxide as a result of a catalytic and reversible cycle. The 
overoxidation of selenoxide to "selenone" does not occur under physiological conditions, 
which is different from its sulfur analogue.  
The oxidation of SeMet leads to the formation of selenoxides and selenones which serve as 
oxidizing species and interact spontaneously with the proteins of cellular thiolstat, and may 
even enter a specific catalytic cycle. There are specific reductants such as methionine 
sulfoxide reductase (MSR) A and B which reduce methionine sulfoxide(s) to methionine(s) 
following a specific redox mechanism [42,43]. The redox pathway involves the reduction of 
oxidized form of MSR (A or B) which itself is mediated by simultaneous oxidation of reduced 
form of thioredoxin (Trx). The oxidised form of Trx is subsequently reduced by Thioredoxin 
Reductase (TR) which oxidises NADPH to NADP
+
 (Figure 4) [42,43]. It is interesting to note 
that mammalian TR contains SeCys at the C-terminal extension [44].  
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Figure 4. A Schematic overview of the redox cycle of oxidized and reduced forms of Met 
mediated by MSR, Trx and TR. 
Selenoxides serve as an important participant for the selenium redox cycle in the fight against 
oxidizing species, such as hydrogen peroxide (H2O2) and peroxynitrite (ONOO
-
) [45]. Further 
oxidation of selenoxides leads to the formation of selenones R1Se(O2)R2, the selenium 
analogue of sulfones, not to be confused with the other equivocal but chemically dramatically 
different selenone (R1C(=Se)R2) the selenium analogue of thione. In contrast to sulfones, 
selenones are rather unstable molecules and are, therefore, relatively rare in nature [30].  
1.5.3. Selenoneine 
Selenoneine is a naturally occurring selenium analogue of ergothioneine (EGT). EGT was 
first isolated by a French pharmacist and chemist Charles Tantet (1847-1917) about more than 
a century ago, in 1909, from the ergot of rye [46]. Several physiological functions of EGT 
have been reported in the literature including chelation of cations, regulation of the immune 
system and gene expression [47-50]. A very strong antioxidant and cytoprotective effect of 
EGT has been reported in the literature [51-60].  
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The selenium analogue of EGT, Selenoneine, has been discovered recently and isolated by 
Yamashita and his colleagues from the blood and tissues of tuna fish [61]. Chemically, 
selenoneine is a thoroughly unique naturally occurring molecule due to the presence of a 
selenourea motif. The molecule is highly sensitive towards oxidation due to the presence of 
the C=Se double bond or C-SeH in the tautomeric form respectively (see Figure 5). The 
presence of the lone pair of electrons on the adjacent nitrogen plays an important role in the 
chemistry of such selenoureas. Similar to the sulfur analogue EGT which exists in a thiol-
thione equilibrium, selenoneine occurs in a specific selenol-selenone equilibrium (Figure 5) 
[62].  
 
Figure 5. Ergothioneine and selenoneine exist in two tautomeric forms each, namely 3-(2-
mercapto-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate (thiol form), 3-(2-thioxo-2,3-
dihydro-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate (thione form), 3-(2-
hydroseleno-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate (selenol form) and 3-(2-
selenoxo-2,3-dihydro-1H-imidazol-4-yl)-2-(trimethylammonio)propanoate (selenone form).  
Selenoneine is apparently involved in the detoxification and metabolism of mercury 
compounds, such as methyl mercury (MeHg) which highlights the metal binding properties of 
this compound. The integration, incorporation and excretion of selenoneine is regulated by the 
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organic cation / carnitine transporter 1 (OCTN1) which is also an interesting transporter of 
EGT, the sulfur analogue of selenoneine [63]. Selenoneine also binds with other metals, 
including iron and has been found to attach to the haemoglobin (in blood) and myoglobin (in 
muscles) and protects them from auto-oxidation induced by iron ions in hypoxia. The 
antioxidant ability of cells and tissues is enhanced in the presence of GPx and several other 
selenoproteins [64]. The major antioxidant mechanism of selenoneine involves its interaction 
with ROS where it serves as an excellent radical scavenger and protects the cells and tissues 
against oxidative damages (Figure 6) [61]. 
 
Figure 6. The naturally occurring small molecule selenium compound selenoneine serves as 
an excellent antioxidant and protects the cells by scavenging harmful radicals which belong to 
the family of ROS. As an excellent complexing agent / ligand system for many heavy metals, 
it also detoxifies methyl mercury in fish. 
These natural RSeS have been explored extensively as redox modulators, antioxidants, 
chemopreventive and anti-proliferative or anticancer agents [30]. There are several other 
examples of RSeS, such as elemental selenium or hydrogen selenide (H2Se), which have also 
been studied in the last couple of years in the context of OS and related diseases [65,66].  
Introduction 
__________________________________________________________________________________ 
14 
 
1.6. From RSeS to drug design 
RSeS provide a solid base for designing selenium-based multifunctional redox modulators to 
achieve better selectivity and reactivity. As described earlier the term RSeS refers to the redox 
modulating and often oxidizing nature of selenium-based organic compounds. Elemental 
selenium and several classes of synthetic organo-selenium compounds could also be 
considered in this context. The application of elemental selenium in the fields of nutrition, 
medicine and agriculture has been investigated in detail [67-70]. Nanotechnology imparts 
several beneficial features to elemental selenium, such as an increased surface area, improved 
bioavailability and enhanced biological activity. Selenium Nanoparticles (SeNPs) can be 
generated mechanically by grinding utilizing a mill and homogenizer, chemically by the 
reduction of SeO3
2-
 and also biologically by employing bacteria, such as Staphylococcus 
carnosus and Bacillus oryziterrae [70]. Among all the types of procedures employed to 
generate SeNPs, biologically produced SeNPs are of particular interest as these particles are 
(i) environmentally friendly, (ii) enhancing the bioavailability of elemental selenium, (iii) 
often covered by a protein coat which inhibits the agglomeration of such particles, and (iv) 
active against their targets, such as a wide spectrum of microbes [70].  
The redox chemistry of SeCys is rather similar to the one of selenides due to presence of the 
selenol/ selenolate group, while the reodox chemistry of SeMet involves selenides, 
selenoxides and selenones. Chemically and also biologically, selenides and selenols are 
interrelated. It has been reported that the metabolic conversion of selenide to selenol results in 
enhanced nucleophilic and cytotoxic activity [71]. Selenoneine is rather exceptional as it is 
neither a classical selenol nor selenide. It contains an interesting selenourea motif in the ring 
which results in a selenone-selenol tautomerism. Unlike thiourea this selenone urea is not 
very stable but can be stabilized by altering the ring or employing certain functional groups to 
stabilize the structure. This information regarding the oxidation state, stability, nucleophlicity, 
Introduction 
__________________________________________________________________________________ 
15 
 
interaction with the cellular cysteine and  proteins could be utilised to design synthetic RSeS. 
The synthetic organo-selenium compounds can range in complexity from simple 
selenocyanates to the products of complicated multicomponent reactions, such as the Click 
combinations or Biginelli reactions. The concept of RSeS could therefore be exploited to 
design synthetic molecules which may serve as promising lead structures from the perspective 
of drug design, as summarised in Figure 7.  
 
Figure 7. The concept of RSeS can be exploited from the perspective of drug design.  
1.7. Seleno-nitrogen compounds 
Seleno-nitrogen compounds represent an interesting class of organo-selenium compounds due 
to the presence of two hetero atoms in the aromatic ring. Ebselen is one of the most important 
members of this class as it is the only selenium containing organic molecule which so far has 
reached clinical trials [27]. Ebselen is a multifunctional agent which interacts with the cellular 
thiols of cysteine proteins, catalyses the reduction of ROS, similar to GPx and serves as an 
excellent oxidant of reduced thioredoxin [28,72]. Ebselen has been explored to serve as 
antioxidant, antimicrobial and cytoprotective agent [28,72]. Selenazolinium salts represent 
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another interesting class of compounds with Se-N bond which have been synthesized recently 
by Pavel Asrenyans and his colleagues [73]. These compounds resemble ebselen in structure, 
and possess an additional positive charge which considerably enhances the electrophilic 
affiliation of the compounds towards nucleophiles including thiols. These selenazolinium salts 
are therefore also more reactive biologically [73]. 
Besides ebselen and selenazolinium salts, there are several other classes of organoselenium 
compounds with different arrangements of selenium and nitrogen, including selenazoles, 
selenadiazoles, selenocyanates, isoselenocyanates and selenoureas.  
1.7.1. The mystery of the selenamide/selenenamide bond (Se-N)  
A cyclic selenamide, also referred to as selenenamide, has been proposed to be formed during 
the catalytic mechanism of GPx-1 as a result of complicated interactions of selenenic acid 
with a particular amide moiety of the protein backbone. This five membered selenamide ring 
serves as an excellent electrophile and subsequently interacts with glutathione to form mixed 
selenosulfides [33]. Based on these considerations several selenenamide-based mimics of GPx 
have been synthesized and their activities have been evaluated [74]. A recent study has 
demonstrated the mechanism of antioxidant activity of several selenenamide mimics based on 
their interactions with nucleophilic aromatic thiols [75].  
Interestingly, the same selenenamide bond also exists in ebselen which belongs to the class of 
selenazolines. Ebselen (Figure 8) contains one nitrogen in the ring and, from a design 
perspective, addition of a second nitrogen atom may lead to the activation of these compounds 
for increased biological activities. Selenadiazoles are heterocyclic compounds which contain 
two nitrogen and one selenium in the heteroatom ring structure. The addition of a second 
nitrogen may decrease the electron density and subsequently enhance the electrophilic 
reactivity of the compounds which is usually desired for biological activity [30]. 
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Selenadiazoles have been proposed to interact with the thiol residues of cellular cysteine 
proteins and thereby exert antimicrobial activity [76]. Several selenazoles have also been 
reported to induce apoptosis in cancer cells by increasing intracellular levels of ROS [77]. The 
generalised structures of selenazoles and selenadiazoles are shown in Figure 8 
 
Figure 8. General representation of selenazoles, selenadiazoles, ebselen and structure of most 
active compounds from the family of selenazolinium salts.  
1.7.2. Selenocyanates 
Selenocyanates represent another attractive class of seleno-nitrogen compounds. 
Traditionally, cyanates have been an interesting class of compounds as they comprise of a 
unique blend of carbon, nitrogen and an element from the chalcogen family with the 
exception of polonium (Po). Inorganic cyanates, such as sodium and potassium cyanates, have 
been considered to be toxic due to several factors, including interactions with components of 
the central and the peripheral nervous system and irreversible binding with iron proteins, such 
as haemoglobin [78-81]. In contrast to inorganic cyanates, the organic cyanates or nitriles, 
have been found to be very useful for biological systems. Organic cyanates have been 
facilitated as an interesting pharmacophore for designing drug molecules. A huge number of 
medicines have been produced employing this interesting motif. The nitrile functional group 
is very strong and stays intact even after metabolism, as observed in several nitrile-containing 
drugs. Vildagliptin, Fadrozole monohydrochloride, Letrozole (with two nitrile groups), 
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Neratinib and Olprinone are a few rather prominent examples of nitrile containing drugs 
(Figure 9) [82,83] .  
 
Figure 9. A few selected examples of nitrile containing drugs. 
It has also been observed that addition of a chalcogen element confers some special 
characteristics to molecules. Thiocyanates, i.e. cyanates containing a sulfur atom, represent an 
interesting class of organic cyanates as they occur naturally in the extracellular fluids of 
mammals. Thiocyanates are either synthesized enzymatically by sulfur transferase, an enzyme 
which transfers sulfur to cyanides, or taken from the diet into the human system. These 
thiocyanates play an efficient role in the defence system of the host by inhibiting the 
metabolism of pathogenic organisms [84,85]. Moreover, they also serve as an integral part of 
the host antioxidant system [86]. Thiocyanates have the ability to interact with the cellular 
thiolstat and redox modulate transformations reversibly [87]. Furthermore, inorganic 
thiocyanates have also been employed in the shampoos for the regeneration of hair [88]. 
Organic thiocyanates, allyl (iso)thiocyanate, benzyl (iso)thiocyanate, phenethyl 
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(iso)thiocyanate and sulforafanes for instance, are widely dispersed in nature, especially in 
cruciferous plants, and are known for their excellent antimicrobial and anticancer activities 
[89-91]. Moreover, allyl isothiocyanate has been reported to serve as an efficient 
multifunctional agent for the treatment of neurodegenerative diseases, cardiovascular 
diseases, diabetes, chronic obstructive pulmonary disease, renal fibrosis and dermatitis 
(Figure 10) [92]. Interestingly, the thiocyanate motif has also been observed in marine natural 
products, such as fasiculin, psammaplin B and 9-thiocyanatopupukeanane (Figure 10) [93-
95].  
 
Figure 10. Nature itsef is an affluent source of (iso)thiocyanates e.g. allyl isothiocyanate, 
benzyl isothiocyanate, phenethyl isothiocyanate, sulforafane, fasiculin, psammaplin B and 9-
thiocyanatopupukeanane, representing excellent agents able to treat various diseases. 
Inorganic salts of thiocyanate, such as potassium thiocyanate and sodium thiocyanate are 
commonly employed in shampoos for the regeneration of hair.  
Moving down the Periodic Table from sulfur to selenium, there is a remarkable change in the 
physical characteristics, chemical reactivity and biochemical and antimicrobial activity of the 
relevant compounds. This could be attributed to the more nucleophilic nature of selenium. 
Moreover, the valence shell electrons in selenium are loosely held as compared to sulfur. 
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Furthermore, selenium cannot form all the kinds of π bonds as sulfur and the bond strength is 
also not very strong as compared to sulfur [96]. Elemental selenium has been proven to be 
biologically more active in various systems compared to sulfur. In the context of cyanates, 
there is not much literature available for comparison, especially in biological systems. Among 
the few reports Krishnegowda et al. have demonstrated that selenocyanates exhibit a higher 
cytotoxic activity against MCF-7 breast cancer cell lines compared to thiocyanates [97].  
Apart from these activities, selenocyanates represent an interesting class of organo-selenium 
compounds which serve as a precursor for various other types of organo-selenium compounds 
classes, such as seleninic acids and diselenides. They have been investigated extensively from 
chemical and biological perspectives but little has been reported about their anti-microbial 
activity. Moreover, the literature also reveals that selenocyanates have mostly been studied 
when attached to some “bioactive” scaffolds which may also influence and mask their very 
own biological activity [98].  
1.8. Selenium based intelligent redox catalysts 
The significance of redox catalysis could be estimated by considering the redox chemistry 
underlying the biological activities of seleninic acids. From the perspective of drug design, 
seleninic acids and their respective deprotonated forms and salts are generally easily soluble 
in many solvents, including aqueous media. Seleninic acids are easy to synthesize, acidic, 
rather reactive and tend to be highly specific for the thiols in general and thiols of the cellular 
thiolstat in particular [99,100]. Seleninic acids are relatively weaker acids than their 
corresponding sulfur analogues by around two pKa units e.g. the pKa values of 
benzeneseleninic acid (PhSeO2H) and Benzenesulfinic acid (PhSO2H) are 4.79239 and 
2.76240, respectively. The relatively higher acidic nature of sulfinic acid is attributed to the 
intrinsic higher electronegativity and enhanced π- electrons accepting tendency of sulfur when 
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compared to selenium. Although, at the moment, the literature lacks information concerning 
the basicity of seleninic acids i.e. pKa of PhSe(OH)
2+
, it can be envisaged that they would be 
significantly more basic in nature than sulfinic acids (as is the case with selenoxides and 
sulfoxides). Hence, acid catalysed substitution reactions of seleninic acid are favoured and 
therefore the reactions involving the reduction of such selenenic acids by thiols are rapid 
[101-103]. Studies performed by the colleagues of Hans J. Reich supported this notion by 
demonstrating that benzeneseleninic acid was rapidly reduced by thiols i.e. in less than 30 s at 
−90 °C, whilst its sulfur analogue did not react with the thiols for weeks even at room 
temperature [96,103]. Interestingly, the literature reveals that the reactions of alkaneseleninic 
acid with aromatic thiols are around 200-fold faster as compared to seleninic acids which are 
part of selenoenzyme, such as selenosubtilisin [102]. These rapid interactions also insinuate 
towards the brief lifespan of the seleninic acids i.e. seconds whilst thiols are found in the 
millimolar concentrations in the cells. The literature also reveals that the rate of reduction of 
seleninic acids by thiols is at least 10
6
 fold faster as compared to their sulfur analogues [96]. 
Moreover, these compounds interact spontaneously with thiols to generate disulfide, 
selenylsulfide and selenol (in some cases only) in several steps (Figure 11). Seleninic acids 
have the potential to modify a total of four cysteine residues by oxidation, still usually their 
reactivity is discontinued with the formation of the selenylsulfide. It is interesting to note that 
at the same time, the final reduced form (selenol) and other intermediates could, theoretically, 
enter a catalytic cycle in the presence of an appropriate oxidizing agent such as hydrogen 
peroxide (H2O2) (Figure 11).  
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Figure 11. The catalytic cycle of seleninic acids represents the significance of selenium-based 
redox catalysts which may serve as intelligent multifunctional agents as they interfere 
specifically with the thiol residues of the proteins of cellular thiolstat.  
The catalytic cycle can be divided into several steps: 
 In the very first step, the nucleophilic selenium atom of seleninic acids interacts with 
the thiol residue of the cysteine protein which leads to the formation of mixed species, 
i.e. selenyl sulfides 
 In the second step, the nucleophilic selenium of mixed selenyl sulfide oxidises another 
thiol of the cysteine protein leading to the formation of disulfides and the selenenic 
acid 
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 Selenenic acid interacts with another thiol of the cysteine protein to form selenyl 
sulfides 
 The mixed selenyl sulfide oxidises one more thiol of the cysteine proteins with the 
formation of disulfides of cysteine proteins and the selenol 
 The selenol may be oxidized by certain ROS, such as H2O2 to selenenic acid 
 Selenenic acid interacts with another thiol of the cysteine protein to form selenyl 
sulfides 
 The mixed selenyl sulfide oxidises one more thiol of the cysteine proteins with the 
formation of disulfides of the cysteine proteins and recycling of the selenol 
This catalytic cycle occurs frequently in the selenium enzymes, such as GPx. Similar catalytic 
cycles have also been observed for some organo-selenium compounds, such as ebselen, and 
involve other selenium species with higher oxidation states [104]. Generally, the mechanism 
of catalysis involves the interaction of substrates with the specific catalyst to generate related 
products. In the context of biological applications at the cellular level, the nature, 
concentration and the impact of these substances i.e. substrate, catalyst and also products on 
the cellular process should be considered.  
Such intracellular catalysis therefore combines several interesting aspects which are 
extremely important from the perspective of drug design. The most distinct features include 
selective targeting of cells under the condition of pre-existing OS, specific interactions with 
the proteins of the cellular thiolstat, absence of intrinsic toxicity and the efficiency even at 
low concentrations. Several organo-selenium catalysts have been reported to exert their 
cytotoxic activity at sub-micromolar concentrations due the presence of  excessive amount of 
substrate, in this case ROS in the target cells e.g. cancer cells without damaging the normal 
cells due to the low concentrations of ROS present there [105,106]. Not surprisingly, several 
studies support the notion of employing specific catalysts as potential drugs which sense a 
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certain biochemical signature i.e. the substrate and reveal their cytotoxic or antioxidant 
potential in response to and by employing the presence of this substrate [106]. 
As a part of this thesis, several compounds from different classes of organo-selenium 
compounds which fall under the umbrella of the RSeS have been designed and synthesized. 
The biological activity of these compounds has been evaluated against a plethora of 
microorganisms and several other targets.  
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2. Aims of the thesis 
The analogy between RSS and RSeS provides interesting insights from the perspective of 
target oriented drug design and synthesis. The first and foremost aim of the current study is to 
employ the concept of RSeS to produce a) selenium analogues of naturally occurring RSS, 
such as thiocyanates, and b) multifunctional redox catalysts, in this case, selenium-based 
hybrid molecules. The second aim of the current study is to determine the biological 
significance of these organo-selenium compounds together with some other RSeS, such as 
ebselen-like selenazolinium salts and inorganic salts of chalcogens. Initially the compounds 
were, therefore, evaluated against a wide spectrum of targets, such as Gram-positive and 
Gram-negative ESKAPE bacteria including the multidrug resistant (MDR) strains, pathogenic 
and non-pathogenic yeasts, multicellular nematodes and certain normal and cancer cell lines.  
The third aim of this study intents to investigate the underlying mode and mechanisms of 
actions of selected compounds. The inorganic salts of chalcogens and selenazolinoium salts 
were subjected to detailed investigations to explore their interactions with cellular targets. The 
fourth aim of this study involves the investigation of drug-like properties and the safety 
profile of some highly effective and (re)active RSeS.  
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Pronounced activity of aromatic selenocyanates
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Selenocyanates represent an interesting class of organic selenium compounds. Due to their similarity
with better known natural (iso-)thiocyanates, they promise high biological activity and may also be
metabolized to other Reactive Selenium Species (RSeS), such as selenols, diselenides and seleninic acids.
Thirteen arylmethyl selenocyanates (1–13) have been synthesized and evaluated for potential antimicrobial,
nematicidal and cytotoxic activity. The compounds exhibit pronounced antimicrobial activity against various
strains of Gram-positive and Gram-negative bacteria and yeasts, including multidrug resistant strains. The
results obtained so far demonstrate that these arylmethyl selenocyanates are also non-mutagenic and have
limited cytotoxicity against human cells. Here, benzyl selenocyanate (1) represents the most active anti-ESKAPE
agent, with potent activity against multidrug resistant MRSA strains (HEMSA 5) – with a competitive MIC value
of just 0.76 mg mL1 (3.88 mM), whereas it exhibits low(er) cytotoxicity (IC50 = 31 mM) and no mutagenicity
against mammalian cells. Due to this selective antimicrobial activity, aromatic selenocyanates may provide an
interesting lead in the development of antimicrobial agents, particularly in the context of drug resistance.
Introduction
Since the discovery of the first modern antibiotics almost one
hundred years ago, substances such as penicillin have served as
important and eﬀective weapons in the prevention and treat-
ment of a wide spectrum of infectious diseases. Nonetheless,
over- and misuse of antibiotics, among various other reasons,
have led to a surge of resistance in pathogenic bacteria, which
has now become one of the biggest threats and challenges
facing humanity.1 The phenomenon of resistance to available
antibiotics has attracted the attention of scientists for over two
decades now, and has led to a considerable demand for the
development of new types of antibiotics against such resistant
strains of bacteria and fungi.
Fortunately, nature itself is an aﬄuent source of antibiotics.
Natural substances acquired from medicinal and culinary
plants, such as garlic and mustard, have been employed
extensively as antibiotics throughout history.2–4 More recently,
such secondary metabolites have become important leads in
the development of new and effective medicines.5–7 These
phytochemicals include alkaloids, flavonoids, terpenes, poly-
phenols and, particularly, organosulfur compounds (OSCs).8–11
OSCs are distributed widely in nature, for instance as allicin in
garlic, ergothioneine in mushrooms, and thiocyanates and
isothiocyanates in cruciferous vegetables, to name just a few
(Fig. 1).12–14 Isothiocyanates and thiocyanates are reactive,
electrophilic substances belonging to the class of natural
Reactive Sulfur Species (RSS) and are cherished for their ability
to randomly modify cysteine proteins and enzymes of the
cellular thiolstat.15 Such a wider ‘‘oxidative onslaught’’ in
microorganisms frequently results in pronounced toxicity, even
in otherwise resistant organisms, and RSS are often seen as
promising candidates in the battle against resistant bacteria
and fungi.14–18
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Compared to RSS, Reactive Selenium Species (RSeS) are
considerably less common in biology. Despite the overarching
importance of this trace element in humans, we actually find
only a handful of selenium secondary metabolites in higher
organisms, such as the ergothioneine–analogue selenoneine in
blue tuna, whereas most selenium in higher organisms is
incorporated in the amino acids selenocysteine and seleno-
methionine and forms part of a range of selenoproteins and
selenoenzymes.19–21
The lack of a wider spectrum of selenium containing secondary
metabolites is rather surprising and somewhat disappointing.
A remarkable upsurge in activity and reactivity is often observed
for the selenium analogues of organosulfur compounds, and
‘‘going for selenium’’ in the form of selenium analogues of
naturally occurring RSS is quite attractive from the perspective of
drug design, especially at a time when certain selenium-containing
organic compounds are receiving renewed attention. Selenazole
compounds, such as ebselen (2-phenyl-1,2-benzoselenazol-3-one),
not only mimic the activity of the selenium enzyme glutathione
peroxidase, they also have already entered clinical trials in
the context of mania and hypomania.22–25 Moreover, naturally
occurring (iso-)thiocyanates, such as allyl isocyanate in mustard
oil, and selenium analogues thereof, e.g. primarily (iso-)seleno-
cyanates, represent a particularly promising class of compounds.
Unfortunately, the most obvious selenium analogues of such
natural antibiotics are either chemically unstable or extraordinarily
difficult to synthesise and to handle because of intense odour
and inherent toxicity.26,27 This is particularly the case for the
respective, chemically simple isoselenocyanates. Then again,
replacement of sulfur with selenium in aromatic isothiocyanates
has been reported to enhance the reactivity of compounds
towards thiols in proteins.28 Additionally, isoselenocyanates
demonstrate a higher reactivity towards GSH, target several
cellular proteins, possess a greater ability to modulate the redox
cycle in cells and also induce elevated levels of apoptosis as
compared to isothiocyanates.28 Since isoselenocyanates have
been explored already for biological applications, for instance
against several kinds of cancers (e.g. lung, colon, liver, prostate
and breast) and infective diseases (e.g.malaria, tuberculosis and
leishmaniasis) we have shifted our focus to aromatic selenocyanates,
which have received less attention and also promise greatly
improved physico-chemical properties.29–32 These compounds are
intriguing as they are not only active on their own, being often
metabolized to a range of other RSeS, such as selenols, diselenides
and seleninic acids.33–37 Once again, such organoselenium
compounds are not ‘‘exotic’’ and – either directly or asmetabolites –
play significant roles in biology.38 Although aromatic seleno-
cyanates so far have mostly been studied when attached to some
other ‘‘bioactive’’ scaffolds which may have influenced or even
dominated their biological activity, they have been reported to
exhibit leishmanicidal activity.35,39,40 Moreover, the dietary intake
of benzyl selenocyanate has been reported to inhibit the incidence
of small intestinal and colon adenocarcinoma.41 Since hardly any
wider investigations of such – chemically quite stable – benzyl
selenocyanates are found in the biological literature, we have
turned our attention to this class of compounds first. Here we
Fig. 1 An ‘‘isosteric replacement’’ of sulfur for selenium is found in nature where it leads from Reactive Sulfur Species (RSS), such as ergothioneine, to
Reactive Selenium Species (RSeS), such as selenoneine. In pharmaceutical research, this strategy encompasses a range of (iso-)selenocyanates based on
naturally occurring allyl(iso-)thiocyanates. Notably, the direct analogues of allyl(iso-)thiocyanates are rather unpleasant substances. The aromatic
counterparts (1–13), shown here with their synthesis and respective percentage yields, are more promising candidates in the context of modern drug
development.
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report the synthesis of aromatic selenocyanate compounds,
including four novel compounds (2, 8, 9 and 13), a pronounced
and even somewhat selective antimicrobial activity against
pathogenic and resistant microorganisms and a set of relevant
pharmacological parameters which indicate a low(er) risk to
human cells.
Results and discussion
Chemical synthesis
Thirteen arylmethyl selenocyanates (1–13, Fig. 1) were designed
and synthesized based on basic pharmacokinetic and pharmaco-
dynamic considerations.42–44 The compounds were produced
from appropriate commercially available arylmethyl halides
and potassium selenocyanate (KSeCN) according to the general
procedure described by Wheeler and Merriam, with minor
modifications (Fig. 1).45 All of the compounds – of which four are
novel – were obtained in good yields (62–88%) and the structures of
compounds 1–13 were confirmed by 1H and 13C-NMR spectroscopy.
Molecular mass and purity were determined by LC-MS (see Experi-
mental section and ESI†).
Crystallographic studies
In order to provide a deeper insight into the structural properties,
two selected compounds (1 and 12) were studied by X-ray crystal-
lographic analysis (Fig. 2 and Table S1 in ESI†). In both crystal
structures, the unit cells consisted of four molecules. The values
of bond lengths formed by the selenium atom for C(sp)–Se were
1.850 Å and 1.837 Å for compound 1 and 12, respectively, whereas
for C(sp3)–Se the bond length was 1.991 Å for both structures.
Similar values were observed in other crystal structures with
selenium atoms. A search of the CSD demonstrated that the
geometry of the methyleneselenocyanate moiety in 1 and 12 is
not exceptional among structures containing this fragment. The
crystal structure of 1 has been determined earlier lacking hydro-
gen atoms.46
Antimicrobial activity
Once available, compounds 1–13 were pre-screened for potential
antimicrobial activity against selected Gram-positive and Gram-
negative bacteria, fungi and multicellular nematodes. The anti-
microbial activity was evaluated in terms of minimum inhibitory
concentrations (MICs) and values were compared to standard
reference antimicrobial agents (Table 1).47–52
Overall, a significant and on occasion astonishingly selective
antimicrobial activity against highly pathogenic organisms has
been observed, frequently overcoming the kind of multidrug
resistance traditional antibiotics are faced with. The impact on
cultured human cells was considerably more modest, pointing
towards a possible selectivity against some – particularly nasty –
pathogens. Indeed, most of the compounds displayed signifi-
cant activities against both Gram-positive and Gram-negative
members of a most obnoxious family of bacteria from the
perspective of resistance, i.e. ESKAPE pathogens, which com-
prise of Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
and Enterobacter species.53
In the case of Gram-positive bacteria, the compounds were
examined against the reference strain (ATCC 25923) and the
multidrug resistant (MDR) clinical isolate of Staphylococcus
aureus (S. aureus, HEMSA 5). It is noticeable that all com-
pounds, except compound 11, displayed MIC values against
the MDR strain which were considerably lower than the ones
for the reference antibiotic oxacillin.47,48 In the case of the most
active compound, i.e. benzyl selenocyanate (1) an excellent
antimicrobial activity was observed against HEMSA 5. Amazingly,
the potency of this compound against the resistant strain (MIC
0.76 mg mL1 or 3.88 mM) was almost one hundred fold higher
than the reference drug oxacillin (MIC 128 mg mL1 or 318.86 mM)
(Table 1).
Other compounds (2, 3, 6, 8, 9, 12 and 13) also demonstrated
anti-Staphylococcal activity with MIC values below 10 mg mL1
(62.50 mM). Once more, these selenocyanates did not discrimi-
nate between reference and resistant MDR strains of S. aureus,
displaying similar antibacterial potency against both, with an
activity comparable to or even slightly higher against the MDR
strain (12). Hence, selenocyanates appear to overcome bacterial
MDR, most likely by circumventing the components responsible
for resistance. Still, the exact biochemical causes for this
Fig. 2 The molecular structures of (a) 1 and (b) 12, with the appropriate
atomic numbering schemes. Displacement ellipsoids are drawn at the 30%
probability level. Partial packing views, indicating the intermolecular inter-
actions in a layer of (c) 1 and (d) 12. The intermolecular interactions are
depicted as dashed lines.
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‘‘resistance busting activity’’ are unclear, and, as mentioned
earlier, may also involve reactive metabolic products of seleno-
cyanates, such as selenols, diselenides and seleninic acids,
which together with the original selenocyanate may interfere
with microbial targets to overcome resistance. Notably, most of
these compounds were considerably less active against the
harmless Staphylococcus strain S. carnosus, with almost twenty
to thirty-fold selectivity for HEMSA 5 over S. carnosus observed
for compounds 12 and 1, respectively. Except for compounds 3, 6
and 13 which inhibited the growth of S. carnosus at the con-
centrations of 13.19, 6.69 and 15.39 mg mL1 (62.50 mM, 31.25 mM
and 62.50 mM), respectively, no significant activity against this
reference strain could be found.
The antibacterial activity of the selenocyanates was not limited to
Gram-positive bacteria. Compound 1 also demonstrated excellent
antimicrobial activity against pathogenic Acinetobacter baumannii
(A. baumannii) and Pseudomonas aeruginosa (P. aeruginosa).
Once again, compound 1, with a MIC of 1.53 mg mL1
(7.80 mM) against A. baumannii and 6.12 mg mL1 (31.25 mM)
against P. aeruginosa, was more potent against these Gram-
negative pathogens when compared to the respective reference
drug, in this case piperacillin with a MIC of 16 mg mL1
(30.92 mM) against P. aeruginosa.49,50 Compounds 2, 3, 6, 9,
12 and 13 also demonstrated a significant, albeit slightly lower
activity against A. baumannii (MIC values 6.57–15.44 mg mL1,
i.e. 31.25–62.50 mM). Although the compounds exhibit selectivity
for both Gram-positive and Gram-negative bacteria, the selectivity
of the compounds against pathogenic strains of Gram-negative
bacteria is particularly stimulating from a pharmaceutical per-
spective, as Gram-negative bacteria are generally more difficult to
target, in part due to the specific structure and limited perme-
ability of their cell wall.54,55
When evaluated against pathogenic yeast Candida albicans
(C. albicans), compounds 1, 3, 5, 7 and 11 revealed an encouraging
growth inhibitory activity at concentrations below 20 mg mL1
(62.50 mM). Compounds 5, 7 and 11 prevailed with MIC values
even below 10 mg mL1 (31.25 mM). The fungistatic eﬀect is lower
compared to clinically relevant antifungal drugs, such as flucona-
zole and itraconazole (MIC values 0.09–4 mg mL1 (0.29–13.06 mM)
and 0.03–2 mg mL1 (0.04–2.83 mM), respectively) (Table 1).46,47
When compared to a non-pathogenic yeast, the fungicidal activity
of compound 7 exhibited a high level of selectivity towards
C. albicans, where it was more than 60-fold more active (MIC of
7.4 mg mL1 (31.25 mM)) compared to baker’s yeast Saccharomyces
cerevisiae (S. cerevisiae)(MIC 460.8 mg mL1 (2 mM)). Compounds 5
and 11 exhibited similar activities, although their selectivity
declined noticeably when compared to compound 7. Nonetheless,
these two compounds still maintained remarkably low MIC
values against pathogenic yeast (6.69 mg mL1 (31.25 mM)
and 7.53 mg mL1 (31.25 mM), respectively) compared to
non-pathogenic S. cerevisiae (MIC 53.52 and 60.25 mg mL1
(31.25–250 mM), respectively). Compound 1, which was extra-
ordinarily active against bacteria, also exhibited some activity
against unicellular fungi, with slightly higher fungicidal activity
against pathogenic C. albicans (MIC 12.24 mg mL1 (62.50 mM))
compared to S. cerevisiae (MIC 24.48 mg mL1 (62.50–125 mM)).
Such outcomes are promising in terms of utilizing these com-
pounds as antifungal agents, for instance in the treatment of
fungal infections, such as cutaneous, oropharyngeal and vulvo-
vaginal candidiasis.56–58
Nematicidal activity
Although often ignored in developed countries, multicellular
microorganisms, such as parasitic nematodes, still represent
important targets in drug design which are particularly diﬃcult
to attack. In order to extend the scope of our preliminary studies,
the series of aromatic selenocyanates (1–13) was evaluated for
nematicidal activity against the agricultural nematode S. feltiae,
which often serves as a simple and reliable representative model
of a multicellular organism (Fig. 3).
After a pre-screen to determine the concentration range
relevant for this organism, compounds were evaluated at four
diﬀerent concentrations, i.e. at 3.75, 7.5, 15 and 30 mM.
A remarkable, concentration-dependent decrease in the viability of
Table 1 Antimicrobial activity of arylmethyl selenocyanates against selected bacteria from non-ESKAPE and ESKAPE families of bacteria and yeasts (1–13)
Compound
MICs (mg mL1)
S. carnosus S. aureus ATCC25923 MRSAa HEMSA 5 A. baumannii 4184/2/5 P. aeruginosa 4600 S. cerevisiae C. albicans
1 24.48 r0.76 0.76 1.53 6.12 24.48 12.24
2 26.27 6.57 6.57 6.57–13.14 52.54 52.54 52.54
3 13.19 6.59 6.59 13.19 26.37 6.59 13.19
4 264.08 16.51 33.02 33.01 33.01 66.04 264.08
5 53.52 Z26.76 426.76 26.76 26.76 53.52 6.69
6 6.69 6.69 6.69 13.38 107.05–210.10 6.69 6.69
7 230.4 14.4–28.8 28.8 14.4–28.8 28.8 460.8 7.4
8 115.28 7.2–14.4 7.2–14.4 7.2–14.4 115.28 28.82 28.82
9 33.13 8.28 8.28 8.28–16.56 66.25 66.25 33.13
10 275.04 34.38 434.38 34.38 34.38 68.76 275.04
11 30.125 482 482 4482 4482 60.25 7.53
12 123.09 15.44 7.72 15.44 246.17 123.09 61.55
13 15.39 7.69 7.69 15.39 246.16 61.56 30.78
Ref. 0.03b 0.45c 128c o4c r16d 0.03–2 f 0.09–4e
a MRSA; methicillin-resistant S. aureus. b MIC values for reference antibiotics: ampicillin. c MIC values for reference antibiotics: oxacillin. d MIC
values for reference antibiotics: piperacillin. e MIC values for reference antibiotics: fluconazole. f MIC values for reference antibiotics:
itraconazole.48–53 Bold denotes significant values.
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the nematodes was observed for all compounds, which was pro-
nounced even at the lowest concentrations employed. Compounds 9
and 11 exhibited the most significant nematicidal activity and
decreased the viability of nematodes to less than 40% at a concen-
tration of 3.75 and 15 mM, respectively. These compounds exhibited
LD50 values of 0.28 mM and 4.90 mM against S. feltiae, respectively.
Compound 1, which has shown considerable antibacterial and
antifungal activity (see above), also exhibited significant nematicidal
activity (LD50 = 6.85 mM) and decreased the viability of nematodes to
less than 40% at the concentration of 15 mM. Other selenocyanates
were less active.
Although practical applications are more speculative at this
time, these results indicate that the aromatic selenocyanates
may also serve as excellent nematicidal agents, possibly against
pathogenic nematodes aﬀecting plants, animals and humans –
clearly a matter for further investigation (Fig. 4).
Cytotoxicity of arylmethyl selenocyanates against mammalian
cells
In medicine, selenocyanates have been associated frequently
with outright toxicity. In order to rule out any major cytotoxicity
against mammalian cells and to investigate whether there may
be any selectivity against microorganisms, compounds 1–12
were investigated for their activity towards two cancer cell lines
of mouse T-lymphoma, i.e., the sensitive (PAR) and the multi-
drug resistant cell line (MDR) transfected with the human MDR1
(ABCB1) gene which codes for the ABC transporter, and a normal
NIH/3T3 mouse embryonic fibroblast cell line as a control.
Compounds 1–12 exhibited some cytotoxicity against the
non-cancerous NIH/3T3 mouse fibroblast cell line at concentrations
ranging from 24 mM to above 100 mM, which was around two to
five-fold lower when compared to the anticancer reference drug,
doxorubicin, and also significantly lower when pitched against the
activity of these selenocyanates affecting various microorganisms
(Table 2). Compounds 4, 5, 7 and 10 were the selenocyanates with
the lowest cytotoxicity against both T-lymphoma cell lines, compared
to doxorubicin. Intriguingly, compounds 1, 2, 3, 6, 8, 9, 11 and 12
were more cytotoxic – and also selective. They displayed significant
cytotoxic activities against the parental and multidrug-resistant
sublines of mouse T-lymphoma cells and were less cytotoxic against
the non-cancerous NIH/3T3 cell line, pointing towards a slight,
three- to ten-fold selectivity against these cancer cells.
It is also notable, that the concentrations required for
cytotoxicity in non-cancerous NIH/3T3 cells are generally two
to three-fold lower compared to the concentrations required for
antimicrobial activity (Fig. 4, see below).
The substantial activity of compounds 1, 3 and 12 against MDR
cells is worth noticing, despite the lack of any selectivity for
particular cell lines. Aromatic selenocyanates 1–3, 6, 8, 9, 11 and
12 may not only be of interest in the context of antimicrobial
action – as anticipated initially – they may also represent a starting
point in the search for anticancer agents with MDR-reversing
properties. Such anti-cancer activity is a very complex issue and
requires further investigations.
Fig. 3 Concentration-dependent activities of the most active selenocya-
nates (from left 1, 9 and 11) against S. feltiae. PBS buﬀer and ethanol
(70% v/v) were employed as negative and positive controls, respectively.
Values represent mean  S.D. *** p o 0.001 and ** p o 0.01.
Fig. 4 Diﬀerent targets aﬀected by a typical aromatic selenocyanate and relevant concentrations required to aﬀect these targets. One may note the
distinct diﬀerences in concentrations required for resistant and non-resistant pathogens, and normal and cancer cell lines (see text for details).
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Pharmacological parameters associated with activity
Since the series of selenocyanates under investigation demon-
strated pronounced antimicrobial and nematicidal activities, it
was considered important to investigate their ‘‘drug-likeness’’
profile. Four compounds (1, 2, 4 and 13) were selected for
further investigations employing in vitro assays indicative of
safety and absorption properties. The mutagenic potential and
membrane permeability of the compounds were evaluated
employing a modified Ames fluctuation assay and in parallel
artificial membrane permeability assay (PAMPA) (see ESI† for
details).53,59–62
Ames fluctuation assay
Since inorganic sodium selenite (Na2SeO3) is reputed for its
toxic and mutagenic actions, the selenocyanates were evaluated
for potential mutagenic potential. The Ames fluctuation assay
was employed to calculate the mutagenic index (MI) and
binomial B-values according to the method described in the
literature.53 Compounds are generally considered mutagenic if
the MI is above 2.0 and B is equal to or above 0.99.53,59,60
Neither the selenocyanates (1, 2, 4 and 13), nor the reference
selenium compound ebselen displayed any mutagenic potential
at concentrations of 1 mM and 10 mM (details in ESI†), therefore
ruling out any major mutagenic potential. Compound 1 exhibited
an MI value of 1.15 (B = 0.74) and 1.20 (B = 0.81) at 1 mM and
10 mM concentrations, respectively.
In vitro PAMPA permeability
The PAMPA permeability screening test imitates the structural
and biological conditions of the cell membrane and allows for a
rapid and simple determination of the passive transport of
a compound through biological membranes, characterized by a
permeability coeﬃcient (Kp). Since some of the aromatic seleno-
cyanates seem to enter cells readily and also appear to circumvent
resistance based on eﬄux transporters, their transport properties
were investigated employing a pre-coated PAMPA Plate System
Gentestt (Corning, Tewksbury, MA, USA), which provides good
predictability and correlation of data for absorption in the human
Caco-2 cell line. The concentrations of the compounds tested in
the donor and acceptor compartments were estimated by capillary
electrophoresis (CE) as described previously.60–62 The data on
permeability obtained was compared to that for selected refer-
ence drugs, i.e., highly permeable caffeine and less permeable
norfloxacin (see ESI† for details).
Notably, all compounds investigated, i.e. 1, 2, 4 and 13,
exhibited good permeability with Kp values above the threshold
for highly permeable compounds (i.e. 41.5  106 cm s1).62
In this context, the highest permeability was observed for
compound 2 (Kp = 3.17  106 cm s1) and compound 1
(Kp = 2.69  106 cm s1) which are comparable in permeability
to the reference drug caﬀeine (Kp = 3.61  106 cm s1).
Whilst permeability may explain the ability of the seleno-
cyanates investigated to enter – and to remain inside – target
cells, the mode(s) of action underlying the biological activities
associated with these compounds are still elusive. Here, one
may speculate that selenocyanates may act as strong electro-
philes, hence widely modifying cysteine thiols and possibly also
amine groups in proteins and enzymes (Fig. 5).63 Such redox
modulating interactions with proteins and enzymes of the
cellular thiolstat may also explain, in part, some of the selectivity
observed for certain bacteria and cell lines. Other activities,
possibly exerted by various metabolic and breakdown products
of the selenocyanates, may also be possible and clearly require
further investigation.
Experimental
Chemical synthesis
1H NMR and 13C NMR spectra were recorded on a Varian
Mercury-VX 300 MHz PFG system in DMSO-d6 at ambient
temperature employing the solvent signal as an internal standard.
The values of the chemical shifts are expressed in d values and the
coupling constants ( J) in Hz. Mass spectra were recorded on a
UPLC-MS/MS system consisting of a Waters ACQUITYs UPLCs
(Waters Corporation, Milford, MA, USA) coupled to a Waters TQD
mass spectrometer (electrospray ionization mode ESI-tandem
quadrupole). The purity of the final products was confirmed by
UPLC/MS to be higher than 95%. Retention times (tR) are provided
in min. Thin-layer chromatography (TLC) was performed on pre-
coated Merck silica gel 60 F254 aluminium sheets.
General procedure for the synthesis of selenocyanates
Selenocyanates were synthesized following the general protocol
described by Wheeler and Merriam with some modifications.45
Alkyl halides (10–20 mmol) were treated with KSeCN (12–25 mmol)
in ethanol (10–20 mL). The reaction mixture was refluxed for 6 h
and progress of the reaction was monitored periodically by TLC.
Table 2 Cytotoxicity of arylmethyl selenocyanates against non-
cancerous and cancer cells
Cytotoxicity against mammalian cell lines
Cpd
Mouse T-lymphoma cells
Non-cancerous NIH/3T3PAR MDR
SIIC50 (mM) SD IC50 (mM) SD IC50 (mM) SD
1 5.84 0.45 7.69 0.66 0.76 31.00 3.24
2 5.33 0.41 9.72 1.1 0.55 55.12 2.81
3 9.03 0 5.95 0.18 1.52 29.58 0.95
4 89.18 2.33 4100 — r0.89 4100 —
5 4100 — 4100 — n.d. 4100 —
6 7.93 0.36 8.08 0.75 0.98 59.94 0.35
7 4100 — 4100 — n.d. 4100 —
8 8.58 0.18 9.64 0.88 0.89 44.73 1.79
9 8.53 0.39 10.32 1.13 0.83 42.17 3.08
10 4100 — 4100 — n.d. 4100 —
11 7.26 0.74 14.09 1.58 0.52 70.08 1.55
12 8.47 0.1 7.05 0.15 1.20 24.18 1.97
DOX 0.42 0.17 2.64 0.09 0.16 13.38 0.98
DMSO 42% v/v — 42% v/v — n.d. 42% v/v —
PAR: parental T-lymphoma cells; MDR: multidrug resistant T-lymphoma
cells overproducing eﬄux pump ABCB1; NIH/3T3: non-cancerous mouse
embryonic fibroblast cells; DOX: doxorubicin; DMSO: dimethyl sulfoxide;
SD: standard deviation; SI: selectivity index; n.d.: not determined.
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After completion, the inorganic salt was separated by filtration
and the filtrate was purified with charcoal, condensed and
crystallized with ethanol, to yield crystals of arylmethyl seleno-
cyanates (1–13).
Compounds 1, 3–7 and 10–12 have been described in the
literature before and analytical data for these compounds is in
agreement with the values reported (see ESI†).40,64,65
4-Methylbenzyl selenocyanate (2)
4-Methylbenzyl chloride (1.4 g, 10 mmol), KSeCN (1.73 g,
12 mmol) and ethanol (10 mL) were employed. Compound 2
was obtained as light crystals. Yield 83.6% (1.76 g, 8.36 mmol);
m.p. = 43–45 1C, TLC Rf (DCM, 100%): 0.51.
1H NMR (DMSO-d6,
ppm): d 7.23 (d, J = 7.62 Hz, 2H, 2C–H), 7.17 (d, J = 8.21 Hz, 2H,
2C–H), 4.27 (s, 2H, CH2), 2.28 (t, J = 9.10 Hz, 3H, CH3).
13C NMR
(DMSO-d6, ppm): d 137.62, 135.65, 129.61, 129.22, 105.39
(Se–CN), 33.08, 21.22. LC-MS: purity 100%, tR = 6.25, (ESI)
m/z: calculated for C9H9NSe [M + H]
+: 105.07, found: 105.02.
3-Chlorobenzyl selenocyanate (8)
3-Chlorobenzyl chloride (3.22 g, 20 mmol), KSeCN (3.60 g.
25 mmol) and ethanol (20 mL) were employed. Compound 8
was obtained as light crystals. Yield 82.55% (3.81 g,
16.51 mmol); m.p. = 40–42 1C, TLC Rf (DCM, 100%): 0.75.
1H NMR (DMSO-d6, ppm): d 7.42 (m, 1H, CH), 7.37 (m, 2H, CH),
7.33 (m, 1H, CH), 4.28 (t, J = 9.15 Hz, 2H, CH2).
13C NMR
(DMSO-d6, ppm): d 141.45, 133.38, 130.95, 129.04, 128.17,
128.00, 105.23 (Se–CN), 31.96. LC-MS: purity 98.95%, tR =
6.24, (ESI) m/z: calculated for C8H6ClNSe [M + H]
+: 125.02,
found: 125.02.
3,4-Dichlorobenzyl selenocyanate (9)
3,4-Dichlorobenzyl chloride (3.91 g, 20 mmol), KSeCN (3.6 g.
25 mmol) and ethanol (20 mL) were employed. Compound 9
was obtained as yellow crystals. Yield 88.2% (4.673 g,
17.64 mmol); m.p. = 76–79 1C, TLC Rf (DCM, 100%): 0.60.
1H NMR (DMSO-d6, ppm): d 7.62 (m, 2H, CH), 7.37 (dd, J1 =
2.12 Hz, J2 = 2.09 Hz, 1H, CH), 4.28 (t, J = 9.15 Hz, 2H, CH2).
13C NMR (DMSO-d6, ppm): d 140.24, 131.29 (4C), 129.67, 105.19
(Se–CN), 31.23. LC-MS: purity 99.49%, tR = 6.86, (ESI) m/z:
calculated for C8H5Cl2NSe [M + H]
+: 158.98, found: 158.97.
1-(Selenocyanatomethyl)naphthalene (13)
1-Chloromethyl naphthalene (3.533 g, 20 mmol), KSeCN (3.6 g.
25 mmol) and ethanol (20 mL) were employed. Compound 13 was
obtained as yellow crystals. Yield 75.5% (3.71 g, 15.1 mmol);
m.p. = 92–94 1C, TLC Rf (DCM, 100%): 0.64.
1H NMR (DMSO-d6,
ppm): d 8.27 (d, J = 8.21 Hz, 1H, CH), 7.96 (dd, J1 = 7.03 Hz, J2 =
7.03 Hz, 2H, CH), 7.49 (m, 4H, CH), 4.78 (t, J = 9.38 Hz, 2H, CH2).
13C NMR (DMSO-d6, ppm): d 134.02, 130.87, 129.21, 128.61,
126.77, 125.73, 124.54, 105.33 (Se–CN), 31.09. LC-MS: purity
94.69%, tR = 6.59, (ESI) m/z: calculated for C12H9NSe [M + H]
+:
141.07, found: 141.03.
X-ray crystallography
Single crystals suitable for X-ray analysis were obtained in
ethanol for 1 and in butan-2-ol for 12 by slow evaporation of
the solvent at room temperature. Intensity data of 1 was
collected on a Bruker-Nonius Kappa CCD four circle diﬀracto-
meter, whereas data for 12 was collected on an Oxford diﬀrac-
tion SuperNova diﬀractometer equipped with a Mo (0.71069 Å)
Ka radiation source. The positions of non-hydrogen atoms were
Fig. 5 Selenocyanates and their metabolites exhibit a wide spectrum of redox activity, which includes electrophilic attacks, oxidative modifications of
thiol and selenol functions in proteins and enzymes, and catalytic metal binding. The considerable impact on the cellular redox homeostasis in general,
and on the cellular thiolstat, in particular, may explain the pronounced biological activities observed as part of this study.
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determined by the direct method employing the SIR-2014
programme.66 Hydrogen atoms bonded to carbons atoms were
included at idealized positions and were refined utilising a
riding model. The aryl hydrogen atoms were constrained with
C–H 0.93 Å, the methylene groups with C–H 0.97 Å and Uiso(H) =
1.2Ueq. The final refinements were performed employing the
SHELXL programme. ORTEP and MERCURY programmes were
employed for molecular graphics.67–69
Compound 1. C8H7NSe, Mr = 196.11, crystal size 0.08 
0.16 0.46 mm3, monoclinic, space group P21/c, a = 5.9880(1) Å,
b = 7.4440(2) Å, c = 17.4880(5) Å, b = 96.277(2)1, V = 774.85 Å3,
Z = 4, T = 100(2) K, 6844 reflections collected, 1786 unique
reflections [Rint = 0.0326], R1 = 0.0226, wR2 = 0.0521 [I 4 2s(I)],
R1 = 0.0226, wR2 = 0.0536 [all data].
Compound 12. C12H9NSe, Mr = 246.16, crystal size 0.25 
0.48  0.60 mm3, monoclinic, space group Ia, a = 8.2486(2) Å,
b = 5.9838(1) Å, c = 20.4158(7) Å, b = 93.097(3)1, V = 1006.23 Å3,
Z = 4, T = 130(2) K, 4415 reflections collected, 2048 unique
reflections [Rint = 0.0300], R1 = 0.0368, wR2 = 0.0921 [I4 2s(I)],
R1 = 0.0397, wR2 = 0.0947 [all data].
CCDC 1819893 and 1819894.†
Antimicrobial activity
The minimal inhibitory concentrations (MICs) were determined
by the standard microdilution method in cation-adjusted
Mueller-Hinton II Broth (MHB, Becton-Dickinson, Germany)
according to the recommendations of the Clinical and Laboratory
Standard Institute (CLSI).70 The compounds (1–13) were evaluated
for their antimicrobial activity against a broad spectrum of
microorganisms, including Gram-positive bacteria (S. carnosus
and S. aureus), Gram-negative bacteria (A. baumannii and
P. aeruginosa) and yeasts (C. albicans and S. cerevisiae). The
values of MIC were recorded after 20 h and 24 h of incubation
with the compounds for bacteria and yeasts, respectively.
Experiments were performed in triplicate and on three different
occasions (i.e., a total of nine repeats for each individual
measurement).
Nematicidal activity
S. feltiae was obtained from Sautter and Stepper GmbH
(Ammerbuch, Germany). The assay was performed according
to an established literature protocol.71,72 Results are provided
as means  SD. GraphPad Prism 5 was employed to perform
the statistical analysis. Statistical significances were calculated
by employing one-way ANOVA, with p o 0.05 considered to be
statistically significant.
Cytotoxicity assays
L5178 mouse T-cell lymphoma cells (PAR) (ECACC Cat.
No. 87111908, obtained from FDA, Silver Spring, MD, USA)
were transfected with pHa MDR1/A retrovirus, as described
previously by Cornwell et al.73 The NIH/3T3 mouse embryonic
fibroblast cell line (ATCC CRL-1658) was purchased from LGC
Promochem, Teddington, UK. The cell line was cultured
in Dulbecco’s modified Eagle’s medium (DMEM, containing
4.5 g L1 glucose) supplemented with 10% heat-inactivated
fetal bovine serum. The cell line was incubated at 37 1C in a 5%
CO2, 95% air atmosphere. Cytotoxicity assays were performed
following the procedures described in the literature.74,75
Mutagenicity assay
The Salmonella typhimurium TA100 strain with base pair sub-
stitution (hisG46 mutation, whose target is GGG) was purchased
from Xenometrix, Allschwil, Switzerland, and employed in the
Ames 384-well microtiter assay.76 Prior to the experiment, the
Salmonella typhimurium TA100 strain was cultivated overnight
(NB-2 liquid medium in the presence of 25 mg mL1 ampicillin).
Then, all of the compounds were assayed according to the micro-
titre liquid Ames fluctuation protocol described in the literature.76
NQNO was utilized as a positive control in the mutagenicity assays.
This reagent causes point mutations in the genome as it induces
G:C - A:T transitions in the Salmonella typhimurium TA-100
strain.76
In vitro PAMPA permeability assay
Compounds 1, 2, 4 and 13, and reference substances were
dissolved in PBS buﬀer (pH = 7.4) from 10 mM DMSO stocks,
according to a protocol described previously.60 The concentra-
tions of compounds and references drugs – in this case
caffeine, and norfloxacin – were estimated in the donor and
acceptor compartments employing capillary electrophoresis
(CE), and calibration curves were determined accordingly.
Finally, the permeability coefficients (Kp, (cm s
1)) of the
compounds tested were calculated employing the formula
provided by the PAMPA plate system manufacturer.60,62
Conclusions
The comprehensive studies presented in the previous sections
have provided new insights into the chemistry and biological
activity of small aromatic selenocyanates, which may be valuable
in the search for new antimicrobial agents. It is particularly
noteworthy that several of the compounds investigated, in
particular benzyl selenocyanate (1), exhibit considerable activity
against Gram-positive and Gram-negative bacteria at concentra-
tions below 1 mg mL1, i.e. at concentrations comparable to or
even below the ones of traditional antibiotics, such as ampicillin,
oxacillin and piperacillin. In the case of the most aggressive
drug-resistant strains of S. aureus, the activity of some of these
selenocyanates even seems to supersede that of oxacillin, which
is not active against these dangerous pathogens. Similarly, an
excellent activity has been noted against Gram-negative organ-
isms, such as A. baumannii and P. aeruginosa, and against the
pathogenic yeast, C. albicans. In the case of yeasts, a surprisingly
high activity against infectious C. albicans and a surprisingly low
activity against baker’s yeast have been observed for several
compounds, which besides an astonishing antibacterial action
also promises some interesting selectivity within the fungal
kingdom.
Additional studies are now required to elucidate the under-
lying mode(s) of action and to enhance the activity and
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selectivity of these agents. Here, the notion of a random attack of
such selenocyanates – and their respectivemetabolites – against a
range of redox-sensitive cysteine proteins and enzymes compos-
ing the cellular thiolstat of the target organisms may serve as a
first hypothesis (Fig. 5). Such a random attack is not uncommon
within the realm of chalcogen redox chemistry and may also
explain the ability of such electrophiles to overcome the tradi-
tional, more focussed mechanisms of drug resistance.
Here, it should be emphasized that such seemingly indis-
criminate modifications of certain proteins and enzymes are
not necessarily preventing selectivity, as the defence mechanisms
against such oxidative onslaughts tend to diﬀer dramatically
between diﬀerent target organisms, and also between targets
and healthy human cells. Notably, our initial studies de facto hint
at a low(er) (cyto-)toxicity against human cells, and relevant
toxicity studies in higher organisms are clearly warranted now.
As for other redox modulating drugs, such a low(er) activity may
be due to the presence of a pronounced antioxidant defence
in human cells, which is often lacking in smaller organisms.
Still, this is speculative at this time and provides space for
further studies, also addressing questions concerning any
indiscriminatory activity and toxicity.
Furthermore, sulfur and selenium compounds are notorious
for their unpleasant odour and one may indeed ‘‘sniﬀ a rat’’
here when considering the smell of several naturally occurring
compounds, such as polysulfanes from garlic and allyl isothio-
cyanate in mustard oil.26,77,78 Since such a smell is due to high
volatility of compounds, and aromatic selenocyanates are fairly
stable solids, odour, and any apparent toxicity which may
traditionally be associated with it, are not of any major concern.
In fact, this aspect has been considered carefully as part of the
selection of suitable compounds, as shown in Fig. 1.
In any case, selenocyanates and their closely related isose-
lenocyanates represent an interesting addition to the menu of
selenium agents able to break through the resistance mechan-
isms of dangerous pathogens.47 Once developed and studied in
more detail, they may spice up the search for the next genera-
tion of eﬀective antibiotics with a specific culinary note of
matured selenium enriched broccoli-mustard.
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Abstract: In view of the pressing need to identify new antibacterial agents able to combat
multidrug-resistant bacteria, we investigated a series of fused selenazolinium derivatives (1–8) regarding
their in vitro antimicrobial activities against 25 ESKAPE-pathogen strains. Ebselen was used as reference
compound. Most of the selenocompounds demonstrated an excellent in vitro activity against all S. aureus
strains, with activities comparable to or even exceeding the one of ebselen. In contrast to ebselen, some
selenazolinium derivatives (1, 3, and 7) even displayed significant actions against all Gram-negative
pathogens tested. The 3-bromo-2-(1-hydroxy-1-methylethyl)[1,2]selenazolo[2,3-a]pyridinium chloride (1)
was particularly active (minimum inhibitory concentrations, MICs: 0.31–1.24 µg/mL for MRSA,
and 0.31–2.48 µg/mL for Gram-negative bacteria) and devoid of any significant mutagenicity in the
Ames assay. Our preliminary mechanistic studies in cell culture indicated that their mode of action
is likely to be associated with an alteration of intracellular levels of glutathione and cysteine thiols
of different proteins in the bacterial cells, hence supporting the idea that such compounds interact
with the intracellular thiolstat. This alteration of pivotal cysteine residues is most likely the result of
a direct or catalytic oxidative modification of such residues by the highly reactive selenium species
(RSeS) employed.
Keywords: selenazolinium salts; ebselen; RSeS; multidrug resistance; MRSA; ESKAPE pathogens;
antibacterial agents
1. Introduction
The emergence and spread of antimicrobial resistance among pathogenic bacteria represents a
major global healthcare problem in the 21st century [1]. A number of common pathogens are reported to
develop resistances against virtually all types or classes of antibiotics [2]. The most troublesome bacteria
Molecules 2017, 22, 2174; doi:10.3390/molecules22122174 www.mdpi.com/journal/molecules
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that pose a growing challenge for healthcare practitioners due to their antimicrobial resistance are
referred as ESKAPE pathogens and include vancomycin-resistant enterococci (VRE), methicillin resistant
Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,
and extended-spectrum β-lactamase (ESBL)-producing or carbapenem-resistant species of the family
Enterobacteriaceae (CRE). The acronym ESKAPE was first proposed by Rice et al. in 2008 to emphasize
the great capacity of these bacteria to “escape” from common antibacterial treatment through rapid
acquisition or development of resistance determinants allowing them to tolerate the antimicrobial
substance(s) [3–6]. Each member of the ESKAPE species is a major source of severe and frequently
lethal diseases in hospitalized patients, and some of them have also successfully spread to community
settings, affecting otherwise healthy individuals [3,7]. Among ESKAPE pathogens, MRSA strains are
the most prevalent Gram-positive bacteria, causing nosocomial infections throughout the world [8,9].
Because of their considerable ability to acquire resistance mechanisms against any antibiotics introduced
into clinical use, the appearance of MRSA strains in hospitals has been associated with substantial
morbidity and mortality rates [9–11]. For multidrug-resistant (MDR) Gram-negative bacteria—namely
A. baumannii, P. aeruginosa, K. pneumoniae, and E. coli, the situation is even more complex and worrisome
as “they represent the problem of multidrug resistance to the maximum” [11]. The therapeutic options
for infections caused by these MDR pathogens are often so extremely limited that, in many cases,
clinicians are left with practically no rational choice of antibiotic treatment [12]. The present situation
is even more threatening when considering the stagnation in the development and approval of novel
antimicrobial agents to treat these pathogens [13]. Therefore, an immediate and continual search for
new antimicrobial agents effective against drug-resistant bacteria, preferentially with a lower risk of
resistance formation, is urgently needed.
In the last few years, selenium-based compounds have received significant attention due to
their unique biological properties which could have multiple prospective applications in clinical
practice [14]. The organoselenium compound ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one,
Figure 1), in particular, is a promising agent for the therapy of various health disorders [15,16]
and is presently undergoing Phase III clinical trials in patients suffering from acute ischemic
stroke and cortical infarct due to its pharmacological efficacy and favourable safety profile [17,18].
Ebselen, like many other organic selenium compounds, is redox-active and able to modify cysteine
residues in proteins and enzymes effectively and selectively. In the presence of elevated levels of
reactive oxygen species (ROS), it can also “turn catalytic”, and its pronounced glutathione peroxidase
(GPx)-like activity promotes widespread interactions with cysteine residues of proteins belonging
to the cellular thiolstat [19], hence resulting in significant decreases of intracellular protein thiols
and activation of various redox-controlled cellular pathways [20]. In addition to various pro- and
antioxidant actions associated traditionally with ebselen, recent studies have also discovered an
excellent bactericidal action against the Gram-positive ESKAPE species E. faecalis/E. faecium and
S. aureus. Curiously, ebselen lacks any major activity against Gram-negative ESKAPE pathogens [21].
This may not be extraordinarily surprising, as ebselen is not the most reactive amongst the selenium
compounds frequently discussed today.
The overarching rationale of this study has therefore been the evaluation of ebselen-like selenium
compounds with similar structural features and specificity towards nucleophilic attack by thiols,
yet with improved reactivity. Within this context, one particular strategy to “improve” the reactivity
of the Se–N bond towards cysteine thiols is the introduction of a positive charge which increases the
electrophilic behaviour of the bond.
As part of this strategy, and during the search for new ebselen analogues containing fused rings
with an endocyclic Se–N bond, a series of selenazolinium salts were obtained [22]. Eight of these
compounds (1–8, Figure 1), have been investigated here for their antibacterial properties against a
variety of S. aureus clinical isolates, as well as representative strains of clinically relevant Gram-negative
ESKAPE bacteria. In addition, initial pharmaceutical safety studies have been carried out, and the
most active compounds have been investigated regarding their potential mechanisms of action.
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described elsewhere [22].
2.2. In Vitro Antibacterial Activity
The in vitro antibacterial activities of the selenazolinium compounds (1–8) were evaluated for
25 strains of ESKAPE b cteria, including 11 G m-pos tive strains (Table 1) and 14 Gram-negative
microbes (Table 2) with a variety of clinical characteristics.
Table 1. Characteristics of the ESKAPE Gram-positive strains used in this study.
Bacterial Strain Relevant Phenotype *
Staphylococcus aureus
ATCC 25923 Reference strain, CC5, MSSA
MM-O058 Clinical isolate, CC121, MSSA, MDR
MM-N072 Clinical isolate, CC152, MSSA, MDR
HEMSA 5 Clinical isolate, MRSA, XDR
LG-N017 Clinical isolate, CC5, MRSA, MDR
MM-O021 Clinical isolate, CC8, MRSA, MDR
R45-CC45 Clinical isolate, CC45, MRSA
R46-CC22 Clinical isolate, CC22, MRSA
USA300 LAC Clinical isolate, CC8, CA-MRSA, MDR
5328 Clinical isolate, CC398, LA-MRSA
Mu50 Clinical isolate, CC5, MRSA, VISA
* CC, clonal complex; MSSA, methicillin-susceptible S. aureus; MRSA, meth cillin-resistant S. aureus; CA-MRSA,
community-acquired MRSA; LA-MRSA, livestock-associated MRSA; VISA, vancomycin-intermediate S. aureus;
MDR, multidrug-resistant; XDR, extensively drug-resistant [23].
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Table 2. Characteristics of the ESKAPE Gram-negative strains used in this study.
Bacterial Strain Relevant Phenotype
Klebsiella pneumoniae
NRZ-00103 Reference strain, KPC-2, MDR, 4 MRGN
KP 21513017 Clinical isolate
KP 1963584 Clinical isolate, OXA-2, MDR, 4 MRGN
Acinetobacter spp.
AC 2151300 Clinical isolate, A. ursingii
AC 1995594 Clinical isolate, A. baumannii complex
AB 4184/2/5 Clinical isolate, A. baumannii
Pseudomonas aeruginosa
ATCC 27853 Reference strain
PA T18 Clinical isolate, MDR, 3 MRGN
PA 54 Clinical isolate, MDR
PA 58 Clinical isolate, MDR
Escherichia coli
NCTC 13351 Reference strain, TEM-3
EC 2151612 Clinical isolate, MDR, 3 MRGN
EC 1995591 Clinical isolate, MDR, 3 MRGN
EC 1227107 Clinical isolate, MDR, 3 MRGN
3/4 MRGN bacteria, multidrug-resistant Gram-negative bacteria. The description 3 or 4 MRGN refers to the
classification of multidrug-resistant Gram-negative bacteria created by the Commission for Hospital Hygiene and
Infectious Disease Prevention (KRINKO) of the Robert Koch-Institute (RKI) in order to outline the resistance pattern
of these pathogens. Bacteria identified as 3 or 4 MRGN are resistant to three or four out of four classes of antibiotic
groups used in the treatment of infections that they cause, respectively [24]; KPC-2, carbapenemase KPC-2; OXA-2,
β-lactamase OXA-2; TEM-3, extended-spectrum β-lactamase TEM-3.
2.2.1. Antibacterial Activity against S. aureus Strains
Antimicrobial activities of compounds 1–8 were investigated against 11 strains of S. aureus
(Gram-positive bacteria) in comparison to ebselen and oxacillin. (Table 3). Results demonstrate that all
selenocompounds (1–8) exhibited excellent antibacterial activities against all S. aureus strains employed
in this study, with MIC values (0.31–3.44 µg/mL) in a similar range as that of ebselen (0.28–2.24 µg/mL).
The same antibacterial effect of compounds 1–8 was observed against both the methicillin-susceptible
S. aureus isolates ATCC 25923, MM-O058, and MM-N072 (MICs = 0.35–3.44 µg/mL) as well as
the methicillin-resistant S. aureus isolates USA300 LAC (CA-MRSA), 5328 (LA-MRSA), LG-N017,
MM-O021, R45 CC22, R45 CC45, HEMSA 5 (HA-MRSA), and Mu50 (VISA) (MIC = 0.31–3.44 µg/mL).
Most of the compounds, except the aldehyde analogue (5), were more active against all MDR and XDR
strains as compared to the reference strain (ATCC 25923, Table 3). This selectivity for the MDR and
XDR (extensively drug-resistant) strains—paired with high activity at low concentrations—turns these
compounds into a promising tool in the fight against drug-resistant bacteria [23]. Moreover, in all cases,
compounds 1–8 exhibited significantly higher antimicrobial activity against MRSA clinical isolates
when compared to the standard drug oxacillin. Among selenazolinium salts, compounds 1 and 6
represented the most effective antimicrobials with MIC values below 1 µg/mL against all but one
MRSA strain, namely HEMSA 5.
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Table 3. Antibacterial activities (MICs) of compounds 1–8 against different strains of S. aureus.
S. aureus Strain
MIC (µg/mL)
OXA 1 2 3 4 5 6 7 8 Ebselen
ATCC 25923 0.25 1.24 1.72–3.44 1.4 1.45 0.72–1.44 0.36–0.72 1.44–2.88 2.88 0.56
MM-O058 * 0.25 0.62 0.86 0.35–0.7 0.36–0.73 0.72 0.36–0.72 0.36–0.72 0.36–0.72 0.56–1.12
MM-N072 * 0.25 0.62–1.24 3.44 0.7–1.4 0.73–1.46 0.72 0.36–0.72 0.72 1.44–2.88 0.56–1.12
USA300 LAC * 12 0.62 3.44 0.7 0.73 0.72–1.44 0.72–1.44 0.36–0.72 0.72–1.44 0.56–1.12
5328 4 0.62–1.24 3.44 1.4 1.45 1.44–2.88 0.72–1.44 0.72–1.44 1.44–2.88 1.12–2.24
LG-N017 * 12 0.62–1.24 0.86–1.72 0.35–0.7 0.73–1.45 0.72–1.44 0.36–0.72 0.36–1.44 0.72–1.44 1.12–2.24
MM-O021 * 64 0.31–0.62 1.72–3.44 0.35–0.7 0.36–0.73 0.36–0.72 0.36–0.72 0.36–0.72 0.72–1.44 0.56–1.12
R45 CC22 64 0.31 0.86–1.72 0.35 0.36–0.73 0.36–0.72 0.36 0.36–0.72 0.36–0.72 1.12
R45 CC45 4 0.31–0.62 1.72–3.44 0.7–1.4 0.36–0.73 0.72 0.36–0.72 0.72 1.44 0.56
HEMSA 5 ** 128 1.24 1.72 1.4 1.45 1.44 0.72 0.72–1.44 2.88 2.8
Mu50 *** 256 0.31–0.62 0.43–0.86 0.7–1.4 0.36–0.73 0.36–0.72 0.36 0.36–0.72 0.72–1.44 0.28
* MDR, multidrug-resistant isolates; ** XDR, extensively drug-resistant isolate; *** VISA strain. Oxacillin (OXA) was used as reference β-lactam antibiotic.
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2.2.2. Antibacterial Activity against Gram-Negative Bacteria
Subsequently, selenocompounds 1–8 were evaluated for their possible inhibitory effects against
four particularly problematic Gram-negative bacterial species belonging to ESKAPE pathogens
(Table 2), and compared to ebselen (Table 4). At least three isolates of K. pneumoniae, Acinetobacter spp.,
P. aeruginosa, and E. coli, including 3 or 4 MRGN strains, were employed in the MIC experiments.
Bacteria identified as 3 or 4 MRGN are resistant to three or four out of four classes of antibiotic groups
used in the treatment of infections that they cause, respectively [24].
Compounds with MICs < 5 µg/mL were considered as highly active ones. In stark contrast
to ebselen, all selenoazolinium salts (1–8) exhibited significant antibacterial activities against at
least two Gram-negative ESKAPE strains. The highest sensibility for compounds 1–8 was observed
for Acinetobacter spp., whereas the reference strain of P. aeruginosa (ATCC 27853) was sensitive
only to compound 1. Interestingly, compounds 1–8 were significantly more active in case of
MDR P. aeruginosa strains when compared to the reference strain. Apart from the ATCC 27853
strain, all selenoazolinium compounds (1–8) exhibited MICs significantly lower than those of
ebselen. Among the selenazolinium salts, compound 1 demonstrated excellent activities against
all ESKAPE strains tested (MICs = 0.31–2.48 µg/mL). A high antibacterial potency was also observed
for compounds 3, 4, and 7, as these selenium compounds were active against 3 MRGN strains of E. coli
and the 4 MRGN K. pneumoniae isolate (Table 4).
2.3. Results of Pharmaceutical Safety
In order to assess some central drug-safety properties for the selenium agents (1–8 and ebselen),
and bearing in mind that certain inorganic-selenium compounds such as selenite (SeO32−) interact
unfavourably with DNA, all relevant compounds were investigated for their possible mutagenic
properties in vitro employing the microtiter Ames test [25–29].
Each experiment was performed in triplicate, and results were given in terms of mutagenic index
(MI), which is the quotient of the number of revertant colonies induced in a test sample and the number
of revertants in a negative control (media with 1% DMSO). A compound is considered mutagenic if MI
is above 2.0 [30,31]. According to the results obtained (Figure 2), neither selenazolinium salts (1–8) nor
ebselen appeared to cause any significant mutagenic changes at the concentrations used (1 µM and 10 µM),
resulting in MI below 2.0, whereas the MI value for reference NQNO (0.5 µM) was 7.24 (Table 5).
When comparing the MI values obtained between the two concentrations tested (1 µM and 10 µM),
however, an evident decrease of MI values for the higher concentration of compounds 4–8 can be noted
(Table 5). This decrease is connected with the cytotoxic activity of 4–8 against the Salmonella typhimurium
TA100 strain, confirmed at 10 µM by Binominal B-values calculated according the manufacturer protocol,
where B ≤ 0.01 indicates the occurrence of cytotoxic events (Figure 2, Table 5).
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Table 4. MIC values of the compounds 1–8 and ebselen against Gram-negative ESKAPE strains.
Bacterial Strain
MIC (µg/mL)
1 2 3 4 5 6 7 8 Ebselen
K. pneumoniae
1 1.24 * 14 1.4–2.8 2.88–5.76 46 46 2.88 5.76 ≥143
2 0.62–1.24 6.88–14 1.4 2.88 35 17 2.88 5.76 108
3 0.62 6.88 1.4 2.88 17 17 1.44–2.88 2.88 72
Acinetobacter spp.
4 0.31–0.62 0.86 0.35–0.7 0.36–0.72 2.88 1.44 0.36–0.72 1.44 18
5 0.62 1.72–3.44 1.4 0.72 2.88–5.76 2.88 0.72 1.44–2.88 27
6 0.31 0.86 0.35 0.36 2.88 0.72–1.44 0.36 1.44 18
P. aeruginosa
7 2.48 110 5.60–11 5.76–12 69 138 17 23 72
8 0.31 1.72 0.7 1.44 12 12 0.72 1.44–2.88 18
9 0.62–1.24 21 1.4–2.8 5.76 12 69 5.76 5.76–12 108
10 0.62 6.88–14 1.4 2.88 17 23 2.88 5.76 27
E. coli
11 1.24–2.48 6.88–14 1.4 2.88 17 12 2.88 5.76 108
12 1.24–2.48 6.88 1.4 2.88 17 12 1.44–2.88 5.76 72
13 2.48 6.88–14 1.44–2.8 2.88 23 12 2.88 5.76 72
14 1.24–2.48 14 2.8 5.76 23 17 2.88 5.76–12 54
* Particularly potent antibacterial activities (MIC < 5 µg/mL) are underlined. In case of MIC ≥ 10 µg/mL, the MIC values are expressed rounded to integers (see Supplementary for details).
Bacterial strains—K. pneumoniae: (1) NRZ-00103, (2) KP 21513017, (3) KP 1963584; Acinetobacter spp.: (4) AC 2151300, (5) AB 1995594, (6) AB 4184/2/5; P. aeruginosa: (7) ATCC 27853,
(8) PA T18, (9) PA54, (10) PA58; E. coli: (11) NCTC 13351, (12) EC 2151612, (13) EC 1995591, (14) EC 1227107.
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Figure 2. Results of the Ames liquid microtiter test and determination of the
mutagenic potential; DMSO (1%)—negative control; ebselen-reference compound;
NQNO (4-nitroquinoline-N-oxide)—mutagenic agent at concentration 0.5 µM; 1–8—selenocompounds
at concentrations 1 µM and 10 µM, respectively; —baseline defining the mutagenicity threshold
(over the line).
Table 5. Mutagenic index (MI) values for ebselen and tested compounds (1–8).
Cpd. MI (1 µM) B MI (10 µM) B
Ebselen 0.69 0.26 0.80 0.46
1 0.69 0.35 1.60 1.00
2 0.96 0.83 1.49 1.00
3 1.97 0.99 0.48 0.06
4 1.49 0.71 0.16 0.00
5 1.81 0.96 0.05 0.00
6 1.33 . 7 0.32 0.00
7 1.28 0.94 0.16 0.00
8 1.28 0.98 0.05 0.00
MI—mutagenic index values for ebselen and selenocompounds 1–8, B—Binomial B-value.
2.4. Studies on the Possible Mode of Antimicrobial Action
Whilst the results obtained so far point towards a considerable and widespread antibacterial
activity associated with virtually all of the selenazolinium compounds under investigation, they do
not reveal any information regarding the possible underlying mode(s) of action. Based on the chemical
structures of these compounds, and their particular reactivity as thiol-selective electrophiles, one may
expect a cert in “redox link” th has been investigated in more detail. Such a link may constitute,
for instance, in the production of ROS, a loss of thiols or a—possibly catalytic—oxidation of specific
thiol groups in particularly redox-sensitive proteins and enzymes of the cellular thiolstat [32–34].
2.4.1. Evaluation of ROS Formation
In order to analyse the effect of the selenazolinium salts (1–8) on intracellular oxidative stress
production in S. aureus, the 2′,7′-dichlorofluorescein diacetate assay (DCFH-DA assay) was performed.
This assay is used routinely in the context of human cell culture and can also be applied to bacteria.
For this purpose, the impact of the most active compounds identified in the MICs assays (1 and 6)
and ebselen on intracellular ROS concentrations was determined with the reference S. aureus strain
ATCC 25923 and the clinical XDR-MRSA isolate HEMSA 5 (Figures S1–S3, Supplementary section).
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Rather unexpectedly, we observed that neither compound 1 nor compound 6 were able to increase
ROS levels in the S. aureus isolates tested.
2.4.2. Reactivity of the Compounds with Thiol Groups
Recent studies have shown that many chalcogen compounds do not generate ROS per se but
instead interfere with their removal by consuming thiol groups [35–37]. Indeed, selenium-based
molecules have been reported to spontaneously react with various biological thiols, including GSH
and cysteine-containing proteins. We therefore performed a standard Ellman’s Reagent DTNB assay in
order to explore the consumption of thiols as possible mode of antibacterial activity of the compounds
tested (Figure 3).
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the selenium compounds would be noted by less TNB production assuming that the products of the 
reaction of N-acetyl-L-cysteine with the selenium compounds do not react with DTNB. As shown in 
Figure 3, the addition of the compounds (1 and 6) at concentrations as low as ≤50 µM to the N-acetyl-
L-cysteine solution significantly decreased the levels of TNB, indicating that the compounds are able 
to modify cysteine, and hence may also be able to attack various proteins and enzymes of the cellular 
thiolstat of the bacteria. The cysteine-modifying activities of the compounds were comparable to or 
even higher than one of the reference molecules—hydrogen peroxide. Interestingly, the more 
pronounced effect was observed for compound 1—which was also very active against bacteria—
followed by ebselen and, to a lesser extent, by compound 6. 
2.5. Structure–Activity Relationship Discussion 
Overall, the studies performed with selenazolinium salts 1–8 have identified this rather unusual 
class of selenium compounds as very reactive chemically and very active biologically. It is highly 
probable that the extraordinary electrophilic behaviour associated with the positively charged Se–N 
Figure 3. Estimation of levels of thiol residues of 100 µM N-acetyl-L-cysteine in the presence of
different concentrations of compounds 1, 6, or ebselen by the DTNB assay. Hydrogen peroxide served
as positive control in the study. The decrease in 2-nitro-5-thiobenzoate (TNB) indicates the ability of the
compounds/H2O2 to modify free sulfhydryl groups of various amino acids of the proteins. It should be
noted that compounds have been added in substoichiometric amounts compared to N-acetyl-L-cysteine
to account for possible thiol oxidation cascades. Statistical significance was assessed by one-way
ANOVA (mean ± SD, n = 5 replicates) followed by Dunnett’s multiple comparisons test. * p ≤ 0.05,
** p ≤ 0.01 and **** p ≤ 0.0001 compared with the control.
The ability of the selenium-based compounds to consume thiol groups was determined with
N-acetyl-L-cysteine, which was exposed to the compounds and whose remaining thiol groups
were subsequently quantified with Ellman’s Reagent DTNB. A loss in thiol groups due to the
presence of the selenium compounds would be noted by less TNB production assuming that
the products of the reaction of N-acetyl-L-cysteine with the selenium compounds do not react
with DTNB. As shown in Figure 3, the addition of the compounds (1 and 6) at concentrations
as low as ≤50 µM to the N-acetyl-L-cysteine solution significantly decreased the levels of TNB,
indicating that the compounds are able to modify cysteine, and hence may also be able to attack
various proteins and enzymes of the cellular thiolstat of the bacteria. The cysteine-modifying activities
of the compounds were comparable to or even higher than one of the reference molecules—hydrogen
peroxide. Interestingly, the more pronounced effect was observed for compound 1—which was also
very active against bacteria—followed by ebselen and, to a lesser extent, by compound 6.
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2.5. Structure–Activity Relationship Discussion
Overall, the studies performed with selenazolinium salts 1–8 have identified this
rather unusual class of selenium compounds as very reactive chemically and very active
biologically. It is highly probable that the extraordinary electrophilic behaviour associated
with the positively charged Se–N motif is responsible for the excellent growth inhibitory
activities on all MDR S. aureus strains. Indeed, the selenazolinium salts 1–8 showed a
comparable influence on S. aureus, often exceeding the one of ebselen, and in all MRSA
strains were considerably more active when compared to the standard antibiotic oxacillin.
Two compounds, the 3-bromo-2-(1-hydroxy-1-methylethyl)[1,2]selenazolo[2,3-a]pyridinium chloride (1)
and the 3-bromo-2-(1-hydroxycyclohexyl)-7-(2-hydroxypropan-2-yl)[1,2]selenazolo[2,3-a]pyridinium
chloride (6) displayed an even stronger antimicrobial effect than ebselen against two of the MRSA strains
tested (LG-N017 and R45 CC22). It is worth emphasizing that their antistaphylococcal activities in form
of MICs are superior to those recently reported for fluoroquinolones and their thiolated analogues [5].
Indeed, the activity of the selenazolinium salts is comparable to that of the most active agents produced
by the latest lines of investigation, e.g., 9,13-disubstituted berberine derivatives [38] or polyhalogenated
2-phenylbenzimidazoles [39].
The studies on the possible mechanisms of action against MRSA strains identified a similar
behaviour of the selenazolinium compounds (1 and 6) and ebselen in all three assays indicating
that the mode of action of the compounds is related to an extensive modification of thiol groups,
possibly in cysteine-containing cellular proteins that are crucial for bacterial survival and growth.
Interestingly, in both cases, i.e., the 3-bromo-selenoazolinium compounds and ebselen, there was only
a slight strain-related discrimination in the antibacterial effects observed, and an even more potent
efficacy in the case of MDR bacteria than in the corresponding reference strains. In contrast to oxacillin,
it is possible that such Se–N endocyclic selenocompounds can overcome certain MDR mechanisms.
There may be various reasons for such behaviour. One may, for instance, consider a widespread and
simultaneous attack of such reactive selenium compounds on various redox-sensitive cysteine proteins,
hence avoiding the kind of resistance associated with “single target” drugs. Alternatively, a significant
consumption of cellular thiols may also trigger unfavourable intracellular signalling processes
which may eventually harm the bacterium affected. In any case, the considerably high activity,
especially against MDR-strains, is of great interest for the current search of antimicrobial agents.
Here, an even more important finding of these studies is the high potency of the
compounds 1–8 against Gram-negative ESKAPE bacteria, which clearly distinguishes these
selenazolinium compounds from ebselen and places them on par with the best anti-ESKAPE
agents found recently, such as isothiazolone [40] or bis-cyclic guanidine compounds [41].
The results obtained here with 14 different Gram-negative strains evidently confirm the promising
properties of the entire group of both, the 3-bromo-selenazolopyridinium chlorides (1–7) and
3-bromo-2-(1-hydroxycyclohexyl)[1,2]selenazolo[2,3-b]thiazolinium chloride (8), against both types
of ESKAPE strains, with special accent on the selenazolopyridinium compounds 1 and 3 (Figure 1,
Tables 2 and 3).
Although it is difficult to discuss probable mechanisms of action, in this case, it is rather obvious
that the charged endocyclic Se–N bond is beneficial for the action against Gram-negative pathogens.
In contrast, ebselen is not active against the latter group of bacteria. Nonetheless, not all selenazolinium
salts were equally active and some differences in activity have been observed within the group (1–8).
Thus, decreased activities were observed for the hydroxycyclohexyl derivatives substituted at position 7
with formyl (5) or hydroxyl-alkyl (6) moieties. A very simple structure–activity relationship (SAR)
analysis suggests that substituents at the pyridine part of the fused rings of compounds 1–7 may
influence the action on Gram-negative pathogens. Thus, a substitution at position 7 could be responsible
for a decrease of antibacterial action. The most active compounds 1 and 3 are not substituted
within the pyridine part of the fused rings as well as they include 1-hydroxy-1-methylethyl- or
1-hydroxycyclohexyl terminal fragments, respectively (Figure 1, Tables 2 and 3). It is not entirely
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clear yet, however, which of the structural properties are really responsible for the outstanding
action observed for some of the compounds, since both the unsubstituted pyridine fragment and the
1-hydroxycyclohexyl one are also present in the less active compounds (2, 4–6 and 8, respectively).
In the case of activity against S. aureus, the most active compounds (1 and 6) are also the more
hydrophilic. The first one (1) possesses the smallest acyclic alcohol moiety, whereas compound 6
includes two hydroxyl groups.
The excellent results obtained for compounds 1–8 in the assays against a panel of 25 ESKAPE
bacterial strains demands further studies for this group of unique compounds in order to evaluate the
pharmaceutical safety profile. In this context, we have already applied the Ames mutagenicity assays,
a gold standard in the initial steps of drug R&D process. The results of low mutagenicity risk for
compounds 1–8 obtained, in resemblance to ebselen, indicate that the new selenazolinium compounds
can be considered as potential candidates for a new drug that is successful in the battle against the
most problematic multidrug-resistant pathogens. Still, a high electrophilic reactivity may also imply a
more random reactivity, for instance, also against human cells, and such issues related to selectivity
should be considered in future studies.
3. Materials and Methods
3.1. Microbiological Assays
3.1.1. Chemical Compounds
The selenazolinium salts: 3-bromo-2-(1-hydroxy-1-methylethyl)[1,2]selenazolo[2,3-a]pyridinium
chloride (1), 3-bromo-2-(1-hydroxy-1-phenylethyl)[1,2]selenazolo[2,3-a]pyridinium
chloride (2), 3-bromo-2-(1-hydroxycyclohexyl)[1,2]selenazolo[2,3-a]pyridinium chloride (3),
3-bromo-2-(1-hydroxycyclohexyl)-5-methyl[1,2]selenazolo[2,3-a]pyridinium chloride (4),
3-bromo-7-formyl-2-(1-hydroxycyclohexyl)[1,2]selenazolo[2,3-a]pyridinium chloride (5),
3-bromo-2-(1-hydroxycyclohexyl)-7-(2-hydroxypropan-2-yl)[1,2]selenazolo[2,3-a]pyridinium
chloride (6), 3-bromo-2-(1-hydroxycycloheptyl)[1,2]selenazolo[2,3-a]pyridinium chloride (7),
and 3-bromo-2-(1-hydroxycyclohexyl)[1,2]selenazolo[2,3-b]thiazolinium chloride (8) were synthesized
according to the procedures described previously [22].
Ebselen was purchased from Sigma-Aldrich (St. Louis, MO, USA). The stock solutions
of the compounds tested were prepared in DMSO/H2O and stored at −20 ◦C until used.
Furthermore, the following solvents and chemical compounds were employed in our studies:
2′,7′-dichlorofluorescein diacetate (DCFH-DA) and oxacillin (Sigma-Aldrich, St. Louis, MO, USA);
2-azobis(2-amidinopropane) dihydrochloride (AAPH; Sigma-Aldrich, Steinheim, Germany);
H2O2 (Life Technologies, Eugene, OR, USA); 5,5′-dithiobis-2-nitrobenzoic acid (DTNB, Ellman reagent;
Sigma-Aldrich, St. Louis, MO, USA); N-acetyl-L-cysteine (Alfa-Aesar, Karlsruhe, Germany);
ampicillin (Polfa Tarchomin S.A., Warszawa, Poland); 4-nitroquinoline-N-oxide (NQNO; Sigma-Aldrich,
Munich, Germany); DMSO and bromocresol purple (Sigma-Aldrich, Munich, Germany); Beef extract,
L-histidine monochloride, and D-biotin (Bioshop, 5480 Mainway, Burlington, Ontario, Canada); peptone
from casein (Merck, Darmstadt, Germany); KH2PO4, K3PO4, (NH4)2SO4, MgSO4 × 7H2O, NaCl,
trisodium citrate dehydrate, and D-glucose (Chempur, Piekary S´la˛skie, Poland).
3.1.2. Bacterial Strains
Twenty-five bacterial strains used in this study are listed in Table 1. S. aureus ATCC®25923TM and
MRSA HEMSA 5 were obtained from the Institute of Hygiene and Tropical Medicine, Universidade
Nova de Lisboa, Lisbon, Portugal; and the A. baumannii isolate AB 4184/2/5 was obtained from
Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Jagiellonian University Medical
College, Cracow, Poland. The remaining bacterial strains were obtained from the stock collection
of the Institute of Medical Microbiology and Hygiene, Saarland University, Homburg, Germany.
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S. typhimurium TA100 strain (Xenometrix, Allschwil, Switzerland) with the base pair substitution
(hisG46 mutation, which target is GGG) was used for the Ames assays indicative of mutagenicity.
3.1.3. Antimicrobial Susceptibility Testing
The minimal inhibitory concentration tests were performed by the standard microdilution method
in cation-adjusted Mueller Hinton II Broth (MHB II, Becton-Dickinson, Heidelberg, Germany) according
to Clinical and Laboratory Standards Institute (CLSI) recommendations [42]. Antibacterial activities
against S. aureus strains were evaluated in comparison with the β-lactam antibiotic oxacillin. The MICs
of compounds 1–8 and ebselen were recorded after 20 h incubation at 37 ◦C. The antibacterial effect
was determined in triplicate in at least three independent experiments.
3.1.4. Determination of Intracellular Oxidative Stress Levels via the DCFH-DA Assay
Reactive oxygen species (ROS) production in S. aureus strains ATCC 25923 and MRSA HEMSA 5
under exposure to a given selenium compound was measured by using the redox-sensitive fluorescent
indicator dye DCFH-DA, according to the protocol published previously [43]. The concentrations of the
compounds were used at levels ranging from 1/2 to 2× their MICs. AAPH at the final concentration of
50 mM was included as positive control in the assay. The fluorescence intensity was detected at 5 min
intervals over a 60 min period using a microplate reader (EnSpire, PerkinElmer, Waltham, MA, USA),
with an excitation wavelength of λex = 480 nm and an emission wavelength of λem = 525 nm.
3.1.5. DTNB Assay
The assay was carried out following the procedure described earlier with a few modifications [44,45].
DTNB was used to quantify the concentration of free thiol groups in the sample. The method is based on the
reaction of this aromatic disulfide with aliphatic thiol groups of a compound to form a mixed disulfide and
2-nitro-5-thiobenzoate (TNB), which ionizes to the TNB2− dianion at neutral or alkaline pH. The reaction
is rapid and stoichiometric, the addition of 1 mol of thiol-containing compound leads to the release of
1 mol of TNB. The latter gives an intense yellow color that can be quantified spectrophotometrically at the
wavelength of 412 nm. The DTNB assay was initiated by mixing 180 µL of 100 µM N-acetyl-L-cysteine
in 0.1 M phosphate buffer solution with either 10 µL of 200 µM, or 1 mM or 2 mM solution of ebselen or
selenazolinium salts exhibiting the highest antibacterial activity in the previous studies (compound 1 and 6),
or hydrogen peroxide, which was used as a positive control in the assay. After 40 min incubation, 10 µL of
DTNB (4 mM) solution was added and the decrease in absorbance was measured spectrophotometrically
by using a microplate reader (EnSpire, PerkinElmer, Waltham, MA, USA) at a wavelength of 412 nm for
10 min at 25 ◦C. One should note that compared to N-acetyl-L-cysteine, the compounds were added in
sub-stoichiometric amounts, as it is possible that such selenium agents react with more than one equivalent
of thiols. It is therefore not expected that all thiols of N-acetyl-L-cysteine are eventually consumed in
this assay.
3.1.6. Ames Test
The alternative Ames test adapted to the HTS microplate format (Xenometrix AG, Allschwil,
Switzerland) was performed using the histidine-dependent Salmonella typhimurium strain TA100,
according to the previously described method of Kamber et al. [25–29]. All the compounds tested
and the reference (ebselen) were evaluated at final concentrations of 1 µM and 10 µM (in the well).
NQNO was applied as a positive standard mutagen control (0.1 µM, 0.5 µM) [29]. Finally, the results
were counted manually and by the use of microplate reader. The mutagenic index (MI) was calculated
next, as the quotient of the number of revertant colonies induced in a test sample and the number
of revertants in a negative control (media with 1% DMSO). A compound is considered mutagenic
if its MI is above 2.0. The Binomial B-values were calculated according to the protocol provided by
Xenometrix AG.
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4. Conclusions
In the present study, a novel group of selenazolinium salts displaying excellent in vitro activity
against ESKAPE pathogens has been described. Similar to ebselen, these reactive selenium species
(RSeS) have demonstrated great potential against 11 strains of S. aureus, including multidrug-resistant
MRSA and VISA clinical isolates. Yet in stark contrast to ebselen, the selenazolinium compounds also
displayed a significant antibacterial action against various members of the Gram-negative ESKAPE
family, including K. pneumoniae, A. baumannii, P. aeruginosa, and E. coli. Moreover, a beneficial
pharmaceutical safety for all selenoazolinium compounds (1–8) has been confirmed in the Ames
mutagenicity assays. These differences between ebselen on one side and the selenazolinium salts on
the other may be explained by differences in reactivity and cellular target(s). Indeed, our preliminary
mechanistic studies indicated that the mode of action for the Se-compounds is likely to be associated
with an alteration of intracellular levels of glutathione and cysteine thiols of different proteins in
the bacterial cells, hence supporting the idea that such compounds interact with the intracellular
thiolstat. Future studies may reveal if this reaction is stoichiometric, or—as anticipated from the low
amounts employed—catalytic with respect to pre-existing ROS and thiols. It is also possible that the
selenazolinium salts react more than once, and that the active species is not the salt itself but possibly a
reactive seleno-sulfide intermediate formed as part of the sequestration by and modification with GSH.
Such investigations may also differentiate between ebselen, which is generally seen as an “antioxidant”
promoting cell survival by reducing ROS in the presence of GSH, and the kind of oxidizing RSeS
employed here, which, due to their high(er) reactivity, seem to attack thiol residues more randomly,
hence modulating the level of GSH yet also affecting proteins and enzymes.
Taking into account such promising properties, we can conclude that the compounds with
the selenazolinium scaffold represent a very promising chemical family in the ongoing search for
new drug candidates that efficiently combat infections caused by highly resistant ESKAPE bacteria.
Thus, the series is worth passing on for further stages of the drug research and development processes
and also for more detailed investigations of the underlying mode(s) of action. At the same time,
the Se–N motif may be refined and “tuned” further to enhance activity and selectivity.
Supplementary Materials: The following are available online. Table S1: Details of MIC values of the compounds
1–8 and ebselen against Gram-negative bacteria, Figure S1: Generation of intracellular ROS in the reference
S. aureus ATCC 25923 strain and in the clinical MRSA HEMSA 5 isolate upon exposure to the different
concentrations of the compound 1, Figure S2: Generation of intracellular ROS in the reference S. aureus ATCC 25923
strain and in the clinical MRSA HEMSA 5 isolate upon exposure to the different concentrations of compound 6,
Figure S3: Generation of intracellular ROS in the reference S. aureus ATCC 25923 strain and in the clinical MRSA
HEMSA 5 isolate upon exposure to the different concentrations of ebselen.
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Abstract: Selenium is traditionally considered as an antioxidant element and selenium 
compounds are often discussed in the context of chemoprevention and therapy. Recent 
studies, however, have revealed a rather more colorful and diverse biological action of 
selenium-based compounds, including the modulation of the intracellular redox homeostasis 
and an often selective interference with regulatory cellular pathways. Our basic activity 
and mode of action studies with simple selenium and tellurium salts in different strains of 
Staphylococcus aureus (MRSA) and Saccharomyces cerevisiae indicate that such compounds 
are sometimes not particularly toxic on their own, yet enhance the antibacterial potential of 
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known antibiotics, possibly via the bioreductive formation of insoluble elemental deposits. 
Whilst the selenium and tellurium compounds tested do not necessarily act via the generation 
of Reactive Oxygen Species (ROS), they seem to interfere with various cellular pathways, 
including a possible inhibition of the proteasome and hindrance of DNA repair. Here, 
organic selenides are considerably more active compared to simple salts. The interference of 
selenium (and tellurium) compounds with multiple targets could provide new avenues for  
the development of effective antibiotic and anticancer agents which may go well beyond the 
traditional notion of selenium as a simple antioxidant. 
Keywords: cellular thiolstat; MRSA; proteasome; redox modulation; resistant bacteria; 
ROS; selenium; tellurium; yeast 
 
1. Introduction 
Selenium as an element in general, and selenium salts and organic selenium compounds in particular, 
are traditionally considered as good antioxidants, as scavengers of free radicals and other Reactive Oxygen 
Species (ROS) [1,2]. Such compounds may be used in nutrition and therapy as chemopreventive and 
perhaps even as anticancer agents. Indeed, various selenium-based preparations, such as selenomethionine 
and sodium selenite (Na2SeO3), are sold freely in many pharmacies and supermarkets as food supplements, 
for the prevention of serious diseases, the stimulation of the immune system and also against more or less 
trivial medical problems, ranging from the common cold to loss of sexual performance and appetite. 
Recent studies performed by us and others have considered a range of such selenium preparations and 
uncovered a more sinister, darker side to this apparently antioxidant element [3]. In a yeast model, 
sodium selenite, for instance, seems to propagate DNA damage, possibly by a direct chemical action or, 
more indirectly, by inhibition of the relevant repair systems. Similarly, there are reports that an excess 
uptake of selenium may not prevent but actually promote the formation of certain diseases, possibly 
even including cancer [4]. 
Not surprisingly, therefore, a more differentiated view on the biological activity and role of selenium 
is required, a view which ultimately may open up new perspectives and avenues in drug design  
and development. Here, the more harmful actions of selenium salts just mentioned at first appear 
disappointing, yet may also be advantageous if their action could be focused on certain targets, such as 
bacteria, plasmodia, fungi or cancer cells [5]. Indeed, tellurium salts have long been considered as 
possible antibiotics, yet the interest in these compounds has declined with the advent of the penicillin  
era [6]. Nonetheless, with the emergence of multi-resistant bacteria, such as methicillin resistant 
Staphylococcus aureus (MRSA), such older remedies currently experience a certain renaissance in 
research and development. 
The main aim of this study has therefore been to “revisit” of the antibiotic activity of certain selenium 
and tellurium salts and organic compounds, this time in particular against resistant strains of S. aureus, 
and in combination with known antibiotics. At the same time, the study has tried to uncover some basic 
aspects of the possible mode(s) of action underlying the (cyto-)toxic activities observed, with a focus 
on redox regulation and interference with key cellular events. 
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2. Results and Discussion 
As part of this study, we have therefore turned our attention to redox active, often catalytic selenium 
compounds in order to explore their potential action against microorganisms, and also to investigate how 
such compounds may impact on a living cell. The chemical structures of the compounds used are shown 
in Figure 1, and these compounds are either available commercially or can be synthesized according to 
known literature methods [7]. 
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Figure 1. Chemical structures of the various selenium and tellurium compounds employed 
as part of this study. It should be noted that the salts (top row) used are highly polar and 
often charged, oxidizing compounds with a specific reactivity. Compounds 1–4, in contrast, 
have been developed over the years as multicenter catalytic sensor/effector agents [8,9]. 
To our great surprise we have found that some simple selenium and tellurium salts act in concert with 
known antibiotics, hence apparently “sensitizing” such bacteria—which include strains of MRSA—
against conventional antibiotics, possibly by inferring with the protease machinery/proteasome. Since 
such salts are not optimized for a particular biological activity and are also unlikely to penetrate the 
cell easily, the concentrations required for action were high. At the same time, the formation of red and 
black deposits could be observed in the case of certain selenium and tellurium salts, respectively. We 
have therefore subsequently turned our attention towards organic selenium (and tellurium) compounds, 
and as expected, these compounds show a higher activity. These findings will now be presented and 
discussed in more detail. 
2.1. Antimicrobial Activity of Selenium Salts 
Since selenium salts, such as Na2SeO3, nowadays are used widely in form of food supplements, we 
have first investigated the potential antimicrobial activity of such simple selenium salts and compared 
this activity to the one of their sulfur and tellurium analogues. This comparison is reasonable as tellurite 
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has long been considered as possible antibiotic and sulfite in fact is used extensively as antimicrobial 
agent to preserve fruits and vegetable nuts. At the high concentrations used, however, neither selenite or 
selenate, nor any of the other salts, showed any notable activity against S. aureus reference strain ATCC 
25923 or multidrug resistant MRSA HEMSA 5 or MRSA HEMSA 5M strains. Indeed, it appears that 
the MIC values against those bacteria in most instances are well above 1 mM, which is much higher than 
those of conventional effective antibiotics (Table 1). 
Table 1. MIC values (in μM) of selected chalcogen salts against three strains of S. aureus. 
Whilst these salts are clearly not active against any of the strains at pharmaceutically relevant 
concentrations, conventional antibiotics show some activity, which is reduced significantly 
in the case of the two resistant strains. 
Compound 
MIC Values (μM) in S. aureus Strains 
ATCC 25923 MRSA HEMSA 5 MRSA HEMSA 5M 
Salt 
Na2TeO3 1000 >2000 >2000 
Na2SeO3 >2000 >2000 >2000 
Na2SeO4 >2000 >2000 >2000 
Na2SO3 >2000 >2000 >2000 
Na2SO4 >2000 >2000 >2000 
Organic 
1 31.25 125 500 
2 250 500 >1000 
3 62.5 62.5 >1000 
4 31.25 31.25 125 
Antibiotic 
Oxacillin 0.45 340 5400 
Cloxacillin 0.42 160 1300 
Ampicillin/sulbactam 0.54 200 200 
Ciprofloxacin 0.38 14 28 
Neomycin 1.0 240 240 
This implies, of course, that neither the selenium nor the tellurium or sulfur salts used as part of this 
study on their own could be employed as antibiotics in practice. Similar results have been obtained 
against Saccharomyces cerevisiae, where neither selenite, selenate nor tellurite showed any significant 
activity against this type of fungus [3]. It should be noted that tellurate (Na2TeO4) was also considered, 
yet could not be tested reliably because of solubility issues in the buffers used which resulted in 
irreproducible results. 
This rather disappointing finding is not entirely unexpected: such simple, highly polar salts are not 
optimized for antibiotic action and their ability to cross cell membranes is limited. Nonetheless, the 
interactions of such salts with biomolecules, especially cysteine containing proteins, are well documented 
in vitro, and one would be tempted to expect at least some impact on the bacterial, fungal or mammalian 
cell. Based on our previous studies in this field, one may speculate, for instance, that some of these 
compounds, particularly Na2SeO3, could “weaken” the cell by promoting oxidative stress and damage 
to DNA or by affecting the cellular thiolstat [10,11]. 
In the case of the organic selenium and tellurium compounds 1–4, a slight antibacterial activity could 
be observed when these compounds were used in micromolar concentrations. While this activity often 
Molecules 2015, 20 13898 
 
 
was distinctively lower than that of the reference antibiotics used, it was much higher when compared 
to the inorganic salts—and was also rather competitive in the case of the drug resistant strains. The 
tellurium compounds 3 and 4, in particular, showed some promising activity against the multidrug 
resistant strain HEMSA-5. The bis-phenyltellanyl derivative 4 was even able to inhibit the growth of 
both MDR MRSA strains (HEMSA 5 and extremely resistant HEMSA 5M) at a dose significantly 
lower than that of most antibiotics tested (excluding ciprofloxacin, see Table 1). 
Since it appears that the selenium and tellurium compounds act differently, probably on different 
targets when compared to the conventional antibiotics, we have posed the question if they may not be 
able to also act synergistically, i.e., in concert with conventional agents. We have therefore investigated 
both, the organic compounds 1–4 and some of the salts in combination with known antibiotic agents, 
such as oxacillin, cloxacillin, ampicillin/sulbactam, ciprofloxacin and neomycin, and indeed observed 
a significant enhancement in the antibacterial activity of such traditional antibiotics, even against some 
of the strains of MRSA (Table 2). Notably, whilst the inorganic salts often enhanced the efficiency of 
the antibiotics used, the organic compounds 1–4 were not particularly useful in those combination 
assays, bearing in mind, of course, that compounds 3 and 4 are fairly potent antibiotics on their own 
(see above). Particularly noteworthy, for instance, is the influence of tellurite (Na2TeO3), which at a 
concentration of just 500 µM enhances the toxicity of oxacillin and cloxacillin against MRSA HEMSA 
5M by more than 1000-fold (Table 2). Notably, Na2TeO3 does not seem to exhibit any synergistic 
effects against the reference strain S. aureus ATTC 25923. 
Table 2. Ability of the chalcogen compounds tested to enhance the antibacterial activity of 
selected antibiotics against S. aureus strains at a chalcogen compound concentration of  
500 µM. Results are expressed as the quotient of the MIC value of antibiotics in the absence 
to that in the presence of the corresponding chalcogen compound. 
Antibiotic Strain of  S. aureus 
Antibiotic Efficacy Enhancement 



+CompAnt
Ant
MIC
MIC
 
1–4 Na2TeO3 Na2SeO3 Na2SeO4 Na2SO3 Na2SO4 
Oxacillin 
ATCC 25923 NE NE * 4 4 NE NE 
MRSA HEMSA 5 NE 16 NE NE NE NE 
MRSA HEMSA 5M NE 1024 NE NE NE NE 
Cloxacillin 
ATCC 25923 NE 2 * 4 4 NE NE 
MRSA HEMSA 5 NE 256 NE NE 32 32 
MRSA HEMSA 5M NE ≥1024 NE NE NE NE 
Ampicillin/ 
Sulbactam 
ATCC 25923 NE 4 * 2 2 NE NE 
MRSA HEMSA 5 NE 8 NE NE 4 4 
MRSA HEMSA 5M NE 8 NE NE NE NE 
Ciprofloxacin 
ATCC 25923 NE NE * NE NE NE NE 
MRSA HEMSA 5 NE NE NE NE NE NE 
MRSA HEMSA 5M NE NE NE NE NE NE 
Neomycin 
ATCC 25923 NE 2 * NE NE NE NE 
MRSA HEMSA 5 NE 4–8 8 NE NE NE 
MRSA HEMSA 5M NE 4 NE NE NE NE 
NE: No enhancement observed; * Tellurite was evaluated at a concentration of 250 µM (i.e., at one quarter of 
direct MIC in ATCC25923). 
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These findings are rather interesting, as they indicate a certain “re-sensitization” of the drug resistant 
strains against classic antibiotics in the presence of certain selenium, and possibly also of tellurium or 
sulfur compounds. Tellurite, for instance promotes the activity of β-lactam antibiotics oxacillin and 
cloxacillin against both strains of MRSA studied, reducing the MIC values for these antibiotics from well 
over 100 µM in the case of HEMSA 5 and over 1000 µM in the case of HEMSA 5M to acceptable 
values in the sub- or low micromolar range, respectively. Furthermore, tellurite increases the action of 
ampicillin combined with sulbactam or of the aminoglycoside antibiotic neomycin against multidrug 
resistant MRSA strains (Table 2). 
This finding in itself obviously is exceptionally attractive from the perspective of future drug combination 
therapies, which to a large extent will rely on this kind of re-sensitization of resistant strains. It also 
agrees with a very recent report in the literature, which shows that nanomolar concentrations of Na2TeO3 
can enhance the toxic effects of the cephalosporin antibiotic cefotaxime against Escherichia coli [12]. 
In this study, the enhancement by Na2TeO3 appeared to be due to a tellurite-induced oxidative stress, 
and a widespread damage to DNA and to proteins, possible mode(s) of action which will be considered 
in more detail as part of the following sections. 
Unfortunately, tellurite is also rather toxic in humans, and the two selenium salts are less active,  
yet also seem to be able to somewhat, up to 4- to 8-fold, promote the toxicity of different antibiotics. 
Na2SeO3, in particular, seems to enhance the action of aminoglycosides against multidrug resistant 
MRSA HEMSA 5, decreasing the effective dose of neomycin required from 240 µM to 30 µM. Bearing 
in mind that Na2SeO3 and Na2SeO4 are considerably less toxic towards humans when compared to their 
tellurium analogues, such an enhancement of antibiotic action in MRSA strains is rather interesting. The 
ultimate choice for a potential therapeutic use therefore may well consider selenite and selenate, rather 
than tellurite, and obviously at concentrations not damaging or even lethal to humans. Incidentally, an 
interesting activity of sulfite and sulfate—which at first were included in the study as controls—could be 
demonstrated. The toxicity of cloxacillin against MRSA HEMSA 5, for instance, is enhanced around  
32-fold by 500 µM concentrations of either Na2SO3 or Na2SO4. Since sulfate, in particular, is non-toxic 
to humans even when administered at higher concentrations, this finding—and the possible usage of 
sulfur-based salts as potential “adjuvants” of this β-lactam antibiotic—should also be considered further 
in earnest. 
2.2. Cellular Targets of Selenite and Selenate in Bacteria and Yeast 
Whilst some of the selenium and tellurium salts studied seem to enhance the antibiotic activity of 
traditional antibiotics, such as β-lactams and aminoglycosides, none of chalcogen salts employed  
was able to increase the bactericidal activity of the fluoroquinolone ciprofloxacin. Ciprofloxacin is an 
inhibitor of bacterial gyrase and hence DNA replication. In contrast, the penicillins interfere with the 
bacterial cell wall synthesis. It is therefore possible that the synergistic effects observed in the case of 
the penicillins point toward a particular mode of action of salts such as Na2TeO3, Na2SeO3 or Na2SeO4. 
We have already mentioned in passing that based on the chemistry and in vitro studies of such redox 
active selenium and tellurium compounds, one would expect a “weakening” of cells exposed to higher 
concentrations of these agents. Although speculative at this time, it may be possible, for instance, that 
these salts interfere with the cell membrane or components thereof. They may hinder the cell wall 
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synthesis, perhaps inhibit (cysteine containing) β-lactamases or stress the cell more generally, for 
instance by the generation of Reactive Oxygen Species (ROS) [13,14]. Indeed, such actions have been 
associated with selenite and tellurite before [3,12]. 
To investigate this issue further, we have therefore considered the impact of these chalcogen  
salts on intracellular ROS levels in S. aureus ATCC 25923, HEMSA 5 and HEMSA 5M using  
2ʹ,7ʹ-dichlorodihydrofluorescein diacetate (DCHFA) as redox-sensitive fluorescent indicator dye. The 
results of this crude ROS assay are presented for the different salts, and against different strains of  
S. aureus in Figures 2–4. 
 
Figure 2. Generation of intracellular ROS by Na2SeO3 in different strains of S. aureus. 
ATCC 25923 (a); HEMSA 5 (b) and HEMSA 5M (c). Data is shown in terms of 
fluorescence emitted (in arbitrary units) by (oxidized) DCFA. The latter is generated by the 
reaction of certain ROS and Reactive Nitrogen Species (RNS) with DCHFA. Different 
concentrations of Na2SeO3 were assayed and the influence of the dual presence of the 
chalcogen salt and an antibiotic (oxacillin) on ROS generation was also evaluated. Values 
shown represent mean values with n = 4. The error bars represent the standard deviation 
(SD) and statistical significances were calculated using an one-way ANOVA followed by 
Bonferroni’s multiple comparison test (Figure 2a,b: p > 0.05; 2c: p < 0.05). 
 
Figure 3. Generation of intracellular ROS by Na2SeO4 in different strains of S. aureus. ATCC 
25923 (a); HEMSA 5 (b) and HEMSA 5M (c). See legend of Figure 2 for further details. 
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Figure 4. Generation of intracellular ROS by Na2TeO3 in different strains of S. aureus. ATCC 
25923 (a); HEMSA 5 (b) and HEMSA 5M (c). See legend of Figure 2 for further details. 
Despite the fact that some of the salts notably increased the efficiency of some of the antibiotics, none 
of the inorganic selenium or tellurium salts studied, either on its own or in combination with oxacillin, 
increased the intracellular levels of ROS significantly. This finding is truly unexpected, as compounds 
such as selenite are known to generate ROS in vitro [15–17], are able to modify the thiol redox state and 
cellular thiolstat, and also have the potential to inhibit enzymes involved in the reduction of oxidative 
stress. Selenite even promotes DNA strand breaks in yeast, possibly also via a redox mechanism [3,18–20]. 
As already mentioned above, there are also reports that K2TeO3 causes a rather strong increase in 
intracellular ROS levels in Gram-negative E. coli [21]. Hence, at least in theory, one may have expected 
an increase in ROS levels for Na2TeO3 and Na2SeO3, either by the direct chemical generation of 
additional ROS, by damaging cellular components subsequently leading to an indirect increase of ROS 
concentrations, or by the inhibition of ROS removal systems. Still, it seems that at the concentrations 
used, none of these redox events plays any major role in the bacteria studied here. 
Noteworthy, there is also no consistent evidence of any “antioxidant” activity of Na2TeO3, Na2SeO3 
and Na2SeO4 in the bacteria investigated. Generally, no significant differences in fluorescence in the 
presence of the compound and the controls were observed. Only in one case, i.e., when the HEMSA 5M 
strain was treated with oxacillin (2400 µg/mL) (with or without the presence of the salts examined), 
could a significant decrease (p < 0.005) of fluorescence compared to the control be observed (Figures 2c, 
3c and 4c). This observed decrease in fluorescence, however, could be due to the high concentration of 
oxacillin used in the ROS assay of this strain, which may have influenced the natural conversion of 
DCHFA into DCFA. Indeed, a specific control (i.e., control 3) has been used in those cases to confirm that 
oxacillin, and not the selenium or tellurium salts, is probably responsible for this particular observation. 
Eventually, one must also emphasize that the DCHFA-assay is widely used yet far from perfect:  
it does not capture all ROS and its outcome is also affected by the activity of certain cellular esterases 
(see also Section 3). Furthermore, Kalyanaraman has suggested that the intracellular oxidation of this dye 
may be mediated to some extent by iron or by cytochrome c [22]. Hence any results obtained by this 
fluorescent assay are rough estimates only and need to be treated with some caution. Whilst the DCHFA 
assay is still widely accepted as a good measure of intracellular levels of ROS, a more sensible, i.e., 
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sensitive and selective method should be used in future studies to confirm the lack of pro-oxidant 
activity of the salts tested. 
More or less by coincidence, however, we have observed a rather different, perhaps not entirely 
expected biological redox activity associated with some of these salts, which may well explain some of 
the findings shown in Table 2 and which may also provide a new angle to the discussion. Upon exposure 
to tellurite and selenite salts, the strains of bacteria investigated changed color, and in fact generated 
and then obviously accumulated solid red and black deposits, which based on previous reports appear to 
consist of elemental selenium and elemental tellurium, respectively. Indeed, a closer look at the literature 
on bacteria dealing with selenium and tellurium salts shows that this finding is not wholly unanticipated. 
Many bacteria, including Halococcus salifodinae BK18, Azospirillum brasilense, Sulfurospirillum and 
Thauera selenatis and also some more common ones such as Pseudomonas, Lactobacillus and Bacillus 
cereus are known to reduce selenite to elemental selenium (nano)particles [23–29]. Thauera selenatis is 
even able to reduce selenate to form elemental selenium deposits. In fact, different species of Lactobacillus 
are used as a natural source of selenium nanoparticles, for instance to enrich probiotics with selenium [30]. 
Similarly, bacteria such as Bacillus beveridgei, Rhodobacter capsulatus and even E. coli readily 
reduce Na2TeO3 to generate elemental tellurium, usually in form of nanoscopic or microscopic rods 
and needles [31–33]. Such a reactive cascade leading to elemental selenium or tellurium is shown in  
Figure 5. It should be noted that to the best of our knowledge, there have been no reports so far that 
Staphylococcus converts selenite or tellurite to elemental selenium or tellurium, respectively. 
Indeed, the elemental precipitates formed not only stain the bacterial cells red or black, those particles 
also exert a massive mechanical stress on the bacterial cell which may ultimately cause cell death via a 
combination of mechanical stresses and unfavorable cellular responses toward them. Eventually, the 
bioreductive formation of these solid deposits in the bacterial cell may weaken the cell and hence may 
also explain—at least in part—the notable efficiency of traditional antibiotics in such compromised cells. 
This process may also contribute to the selective action of such simple chalcogen salts, as mammalian 
cells do not reduce selenite to elemental selenium. Here, selenite is mostly “sequestered” chemically 
by glutathione (GSH) in form of glutathione selenotrisulfide (GSSeSG). The latter is reduced further to 
hydrogen selenide (H2Se) which either serves as a selenium source for the synthesis of selenocysteine or 
is methylated to dimethylselenide (CH3SeCH3) and ionic trimethylselenonium ((CH3)3Se+) and excreted 
(Figure 5) [34,35]. In any case, mammalian cells normally do not form solid selenium or tellurium 
particles and hence are not affected by the mechanical stresses and toxicity caused by such particles [36]. 
Since the reduction of salts such as Na2SeO3 often proceeds spontaneously in the presence of thiols 
(such as GSH), another mode of (cytotoxic) action has been discussed for various selenium and tellurium 
compounds [37]. The underlying chemical mechanism includes the—probably spontaneous and more 
or less random—reaction of such compounds with thiol groups in proteins. Such reactions result in 
various posttranslational oxidative modifications which may also impact on the function and activity of 
the proteins and enzymes affected. Since many cysteine proteins and enzymes are involved in pivotal 
cellular processes (metabolism, signaling, maintenance of redox homeostasis etc.), and hence have 
recently been subsumed under the notion of the “cellular thiolstat”, a modification of their cysteine 
residues and thus function and activity may have serious consequences for the cell [10]. 
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Figure 5. Known bioreductive pathways for SeO32− (and TeO32−) in certain bacterial cells. 
These pathways often terminate in the formation of (solid) elemental selenium and tellurium 
(nano)particles, which subsequently may cause damage to the cell. In our studies, it appears 
that selenite (SeO32−) and tellurite (TeO32−) are also reduced by S. aureus, as different reports 
have observed similar changes in color and the formation of deposits and have linked these 
physical changes to the formation of selenium and tellurium, respectively. In sharp contrast, 
mammalian cells tend to by-pass the “zero oxidation state” and form H2Se as a valuable raw 
product for the synthesis of the amino acid selenocysteine, whilst excess selenium is excreted 
in form of methylated products. Hence the bioreductively generated toxicity of selenium and 
tellurium (nano)particles is probably more or less specific for lower organisms. 
As part of our study, we have therefore considered if such compounds also interact with key cellular 
components or events, especially those which are related to the cellular thiolstat and whose inhibition 
may be highly detrimental to the cell. As part of this search for potential protein targets, we noticed a 
significant inhibition of the proteasome in yeast (Figure 6). It should be pointed out that S. cerevisiae 
was used as model as the yeast proteasome can be studied reliably in isolation as well as in the intact cell. 
Here, Na2SeO3 and especially Na2SeO4 were most active. The impact of Na2SeO4 on proteasome activity 
was observed at higher micromolar concentrations and, at a concentration of 1 mM, Na2SeO4 reduced the 
chymotrypsin-like activity of the yeast proteasome in intact cells significantly, to less than 25%. 
Arguably, these concentrations of selenate are high and not relevant physiologically. Still, one needs 
to bear in mind that these experiments were performed with intact cells, and intracellular concentrations 
of Na2SeO4 may be lower. In fact, the known proteasome inhibitor bortezomib, which was used in this 
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part of the study as positive control, failed to inhibit proteasome activity in yeast cells altogether when 
used at its standard concentration of 1 micromolar. Whilst bortezomib and similar inhibitors penetrate 
human cells readily, they cannot penetrate wild-type yeast cells due to an inherent impermeability of the 
cell wall or membranes [38]. For this reason, yeast has been used simply as a model system, and not as 
a target for therapeutic intervention. 
Notably, both selenium salts did not inhibit the trypsin-like activity and Na2TeO3, often considered 
as the most active of these chalcogen salts, had no inhibitory effect on the yeast proteasome under the 
conditions used. Indeed, at closer inspection, it even appears that Na2SeO3 and Na2TeO3 may actually 
stimulate the trypsin-like activity, although those increases are statistically not significant (Figure 6b). 
 
Figure 6. Inhibition of the proteasome in intact cells of S. cerevisiae (chymotrypsin-like 
activity (a) and trypsin-like activity (b)). Data was obtained from cell extracts after 3 h 
incubation in the presence of 1000 µM of tellurium and selenium salts. Values represent 
means with SD bars from at least three independent experiments, and statistical significances 
were calculated using a one-way ANOVA followed by Bonferroni’s multiple comparison 
test. * p < 0.05. 
Once more, one may speculate that the compounds employed are able to react with thiol groups in 
proteins, and therefore may also interfere with and inhibit a range of proteins and enzymes, including 
parts of the proteasome, either by a direct modification of cysteine residues in components of the 
proteasome itself or by a widespread modification of proteins which then end up and “overload” the 
proteasome in a detrimental manner. Indeed, the notion that thiol-selective yet otherwise unspecific 
(re-)agents may be able to modify a wide range of cellular, redox-sensitive cysteine-proteins, which 
subsequently not only lose their function and activity, but also end up as “garbage” and overload the 
proteasome, is highly stimulating and deserves a more detailed consideration in the future. 
On the one side, these findings are rather instructive, as the proteasome represents an important target 
in modern therapy. In eukaryotes, the ubiquitin-proteasome system is the main proteolytic system, whilst 
in bacteria there are different proteolytic complexes that are directly linked to bacterial virulence [39,40]. 
Not surprisingly, the proteolytic machinery is being considered as a promising therapeutic target, 
especially in multi-resistant bacterial species [41]. Here, fellutamide B acts as inhibitor of the 
Mycobacterium tuberculosis proteasome, whilst an inhibitor of the protease ClpXP increases the sensitivity 
of methycillin-resistant S. aureus and Bacillus anthracis to antibiotics that act on the bacterial wall 
(synthesis) and membrane [42,43]. Indeed, such observations on the “re-sensitization” of the drug 
resistant strains against conventional antibiotics acting on the cell wall synthesis via an inhibition of 
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the proteasome mirror most of the still preliminary findings of our present study [39–43]. It is therefore 
a highly rewarding task to study the impact of selenium food supplements and organic selenium 
compounds on different proteolytic systems/proteasomes (e.g., bacteria, fungi, human cancer cells, 
normal cells) more extensively in the future. 
On the other side, the proteasome represents probably just one target for salts such as Na2SeO3 and 
Na2SeO4. There may be many other—yet unidentified—targets, and some of them may also differ 
between bacterial, fungal and mammalian cells, depending on the specific components of the respective 
cellular thiolstat and the metabolic processes in action (such as specific bioreductive pathways). 
In any case, the observation that simple salts, such as Na2SeO3, are able to compromise bacterial 
cells, even employing some redox driven “nanotechnology”, underlines the considerable interest in 
redox active and catalytic selenium compounds—some of which form part of our daily nutrition—and 
their potential uses in medicine. 
2.3. From Simple Selenium Salts to Redox Modulating Selenium Drugs 
Whilst the results obtained so far for Na2SeO3 and Na2SeO4 (as well as for Na2TeO3) are interesting, 
such compounds are not particularly useful from a pharmaceutical point of view, not least because of 
the high concentrations required for a significant activity. As already mentioned, we have therefore 
investigated some of the most interesting findings obtained as part of this study further, this time 
employing some of our most potent redox modulating selenium and tellurium agents (compounds 1–4 
in Figure 1) [5,7,44,45]. Since these compounds have been designed as potential therapeutic agents 
(for instance considering reactivity, stability, pharmacokinetics, Lipinski’s “Rule of Five”, etc.), it was 
hardly surprising to find a pronounced antibacterial activity for the selenium compound 1 against  
S. aureus ATCC25923 with MIC values as low as 31.25 µM. Interestingly, the two tellurium compounds 
3 and 4 were even rather active against the MRSA strain HEMSA 5, with MIC values of 62.5 µM and 
31.25 µM, respectively. These MIC values are rather low, also when compared to the MIC values 
listed for some of the conventional antibiotics in Table 1. Compound 4, which contains two tellurium 
centers and a quinone moiety, therefore seems to be particularly promising as a potential antibacterial 
agent, and on its own [46].  
When considered in combination with traditional antibiotics, such as oxacillin, these compounds did 
not enhance the activity of the antibiotics used. Yet again, this is hardly surprising. The special 
bioreductive “chemistry” witnessed in bacteria in the case of salts such as Na2SeO3, Na2SeO4 and 
Na2TeO3, for instance, is notably absent for compounds 1–4. First and foremost, no color changes were 
observed when the organoselenium and organotellurium compounds were used. Secondly, there was 
also no evidence of any deposit formation when the cells were incubated with the organic selenium and 
tellurium compounds. Hence based on this evidence, it appears that no elemental selenium and tellurium 
particles similar to the ones observed for the salts were formed and that the kind of mechanical and 
(bio)chemical stresses discussed for compounds such as Na2SeO3 and Na2TeO3 was therefore almost 
certainly also absent. 
Besides simple changes in color, these differences in “chemistry” between the inorganic and organic 
selenium and tellurium compounds obviously translate into further differences in biochemical activity. 
The organic compounds employed contain several redox active, catalytic centers and are known to 
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interfere with the intracellular redox homeostasis in human cells. As part of a related study, it has 
moreover become apparent that such compounds, especially compounds 2 and 4, are able to interfere 
with proteasomes in intact cells as well as with isolated human proteasomes, where those two 
compounds at a concentration of just 1 µM reduce chymotrypsin-like activity by 80% and trypsin-like 
activity by 90%. We also know from our previous studies that these compounds inhibit mammalian 
thioredoxin reductase (TrxR) in vitro, and at rather low concentrations. The selenium compound 2, at 
just 1 µM, reduces TrxR activity to less than 50%, whilst the tellurium compound 3 is even more active, 
with just 60% of the original TrxR activity remaining when used at 500 nM and less than 20% TrxR 
activity remaining when used at an 1 µM concentration [47]. There is also evidence that selenium 
compounds closely related chemically to 1 and 2 interfere with protein synthetic pathways and ultimately 
protein synthesis [47]. 
3. Experimental Section 
3.1. Materials, Solvents and Bacteria 
3.1.1. Materials 
Chemicals, including the various sulfur, selenium and tellurium salts, educts and solvents for the 
chemical synthesis, and substances used for yeast cell culture were purchased from Sigma-Aldrich 
(Steinheim, Germany). Sodium selenite (Na2SeO3) and sodium tellurite (Na2TeO3) were obtained from 
Merck KGaA (Darmstadt, Germany). Sodium sulfite (Na2SO3), sodium sulfate (Na2SO4), the antibiotics 
oxacillin, cloxacillin, ampicillin/sulbactam, ciprofloxacin and neomycin and the fluorescent redox indicator 
dye 2ʹ,7ʹ-dichlorodihydrofluorescein diacetate (DCHFA) were purchased from Sigma-Aldrich (Poznań, 
Poland). Chemicals were used without further purification unless stated otherwise. Compounds 1–4 
were synthesized according to established literature procedures and purified. Their analytical data  
(1H-NMR, 13C-NMR, mass spectrometry) was in accordance with values reported in the literature [44]. 
The fluorescent substrates required for measurements of the proteasome activity (suc-LLVY-AMC and 
z-ARR-AMC) were purchased from Calbiochem (Merck Chemicals GmbH, Schwalbach, Germany). 
3.1.2. Solvents 
Distilled water (Telmed Destylator DE 8/70, Warsaw, Poland) was used as solvent for the preparation 
of Mueller-Hinton Broth (MHB) media and all antibiotic stock solutions. MHB medium was sterilized 
by autoclaving at 121 °C for 15 min. DCHFA stock solution (2 mM) was prepared in pure ethanol (≥99.8%, 
Avantor Performance Materials Poland, Gliwice, Poland). MilliQ water (resistance ≥ 18 MΩ·cm−1) 
was used for the studies involving S. cerevisiae. 
3.1.3. Bacterial Strains 
Wild-type S. aureus American Type Culture Collection ATCC 25923 (oxacillin MIC 0.2 µg/mL) and 
clinical methicillin resistant MRSA strains HEMSA 5 (oxacillin MIC 150 µg/mL) and MRSA HEMSA 
5M (oxacillin MIC 2400 µg/mL) were used as part of this study (Instituto de Higiene e Medicina 
Tropical, Universidade Nova, Lisbon, Portugal). 
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3.2. Microbiological Activity Assays 
The impact of compounds 1–4 and inorganic salts was evaluated in three strains of S. aureus:  
the reference strain ATCC 25923 and the methicillin resistant strains MRSA HEMSA 5 and MRSA 
HEMSA 5M. Minimum inhibitory concentrations (MICs) of oxacillin, cloxacillin, ampicillin/sulbactam, 
ciprofloxacin and neomycin, as well as MICs of compounds 1–4, Na2TeO3, Na2SeO3, Na2SeO4, Na2SO3, 
and Na2SO4, i.e., the intrinsic antibacterial activity of the compounds, and the ability of the selenium 
and tellurium compounds to enhance the activity of the above-mentioned antibiotics were assessed by 
a broth microdilution method in Mueller-Hinton Broth (MHB) according to Clinical and Laboratory 
Standards Institute (CLSI) recommendations. The MICs were recorded as the lowest concentration of 
the compound or of the antibiotic inhibiting visible growth of bacteria after a 16 h incubation at 37 °C. 
In the first step, intrinsic antibacterial activity of each compound was examined. Subsequently, the 
MICs of oxacillin, cloxacillin, ampicillin/sulbactam, ciprofloxacin and neomycin were determined in 
the absence and presence of the compounds to investigate any synergistic effects. In order to avoid any 
significant toxicity of the selenium and tellurium compounds in this step, their concentrations were no 
greater than a quarter of their respective MIC values. All microbiological assays involving bacteria 
were performed in at least two repetitions, whilst the studies with yeast were performed in triplicate 
and on three different occasions. 
3.3. Determination of Intracellular Levels of Oxidative Stress via the DCHFA Assay 
Intracellular levels of ROS were estimated using the fluorescent dye DCHFA. The latter is a  
non-polar dye which can cross cell membranes and becomes trapped inside cells by deacetylation. The 
deacetylated form subsequently reacts with certain ROS to produce 2ʹ,7ʹ-dichlorofluorescein (DCFA), 
the oxidized, fluorescent form of DCHFA. It should be noted that certain ROS, such as the hydroxyl 
radical (•OH) or hydrogen peroxide (H2O2) react better with DCHFA in this assay compared to other 
ROS, and that oxidation can also be triggered by certain Reactive Nitrogen Species (RNS) [22,48]. 
As part of this assay, the reference strain S. aureus ATCC 25923 and the clinical strains S. aureus 
MRSA HEMSA 5 and MRSA HEMSA 5M were grown in Mueller-Hinton Broth (MHB) at 37 °C with 
shaking until reaching an optical density of 0.5 at 600 nm (OD600 = 0.5). At this point the bacterial 
cells were loaded in a 96-well plate and treated with different concentrations of Na2TeO3, Na2SeO3 or 
Na2SeO4 (0.125, 0.25, 0.75 and 1 mM for S. aureus ATCC 25923 and 0.25, 0.5, 1 and 2 mM for  
S. aureus MRSA HEMSA 5 and MRSA HEMSA 5M). ROS levels in bacterial cells were also 
investigated after adding both an inorganic salt (Na2TeO3, Na2SeO3 or Na2SeO4) and oxacillin at the 
concentrations employed in the microbiological assays (0.25 mM and 0.2 µg/mL for the S. aureus 
ATCC 25923 strain, 0.5 mM and 150 µg/mL for the S. aureus MRSA HEMSA 5 strain or 0.5 mM and 
2400 µg/mL for the S. aureus MRSA HEMSA 5M strain, respectively). 
Next, 10 µM (final concentration) of DCHFA solubilized in ethanol (a 2 mM stock was prepared 
prior in ethanol and kept at −20 °C in the dark until further use) were added to the bacterial cultures 
and incubated at room temperature in the dark for 1 h. The samples were subjected to fluorescence 
spectrophotometric analysis. The fluorescence intensity was measured at 5 min intervals over a 60 min 
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period using a microplate reader (EnSpire, PerkinElmer, Waltham, MA, USA), with an excitation 
wavelength of λex = 480 nm and an emission wavelength of λem = 525 nm. 
3.4. Inhibition of the Proteasome of S. Cerevisiae 
Treatment of yeast was carried out according to the method reported recently by Letavayová et al. [49]. 
Briefly, S. cerevisiae was placed on Yeast Extract-Peptone-Dextrose medium (YPD medium) at 37 °C 
overnight. Inocula were prepared by suspending colonies of these cultures in fresh YPD broth until the 
cell suspension reached a density of 2 × 107 cells/mL. Yeast cells were then incubated with 1000 μM of 
compounds at room temperature during 3 h under constant shaking [49]. By the end of the treatment, 
cells were collected by centrifugation and washed twice with phosphate buffered saline (PBS). 
Cell pellets were resuspended in extraction buffer containing 50 mM Tris-HCl, 150 mM NaCl,  
1 mM EGTA, 10% (v/v) glycerol, 0.5% (v/v) Nonidet P-40 substituent, and 1 mM MgCl2 (pH 7.5). The 
cells were lysed by sonication followed by 25 min incubation on ice and centrifugation at 15,000 g for 
30 min. The total protein content in the supernatant was then assessed by the Bradford assay.  
Proteasomal activity was determined in cell extracts by incubating aliquots of total cellular protein 
(25–50 μg) at 37 ± 1 °C with the following fluorogenic substrates: suc-Leu-Leu-Val-Tyr-AMC  
(suc-LLVY-AMC; indicative of chymotrypsin-like activity) and z-Ala-Arg-Arg-AMC (z-ARR-AMC; 
indicative of trypsin-like activity). Fluorescence was recorded for 45 min (excitation wavelength of  
λex = 380 nm and an emission wavelength of λem = 460 nm). 
In each individual experiment, the control (untreated sample) was set at 100%. Final data represents 
the average of three independent experiments. Results were expressed as mean ± SD and the statistical 
significance was determined by one-way ANOVA followed by Bonferroni’s multiple comparison test. 
A value of p ≤ 0.05 was considered as statistically significant. 
4. Conclusions 
Eventually, we have been able to demonstrate that different selenium and tellurium compounds, 
ranging from selenite used as a selenium food supplement to multi-redox center organic molecules, are 
biologically active, also against some rather serious pathogens (such as two strains of MRSA). These 
compounds can either act on their own (such as compounds 1–4) or in concert with traditional antibiotics. 
The role of selenite and other selenium supplements in fighting bacterial infections is therefore of 
considerable interest, especially since those compounds are also known to stimulate the human immune 
defense and to increase the antioxidant capacity—both highly beneficial processes during an infection. 
Likewise, the biological chemistry of such compounds is truly fascinating and may combine different 
aspects of redox modulation and bioreductive formation of nanoparticles. No doubt, the relevant cellular 
targets, events, processes and subsequent biological activities certainly need to be studied in considerable 
more detail in the future. Here, the emerging selective fluorescent staining, quantification and microscopy 
techniques, together with classic activity assays and Western Blots will enable us to perform the kind 
of redox-related “intracellular diagnostics” which is now required to further illuminate the underlying 
cellular targets and processes [3]. Eventually, such knowledge may enable us to employ selenium, in 
its various chemical compositions and forms, effectively, in medicine and perhaps even in agriculture, 
and in the long run to enjoy fully probiotic drinks laced with natural selenium nanoparticles [50]. 
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4. Discussion 
Several Reactive Selenium Species (RSeS) demonstrated excellent activity against a 
broad spectrum of microorganisms and especially against multidrug resistant strains 
(MDR). The significant antimicrobial activity of these compounds supports the initial 
hypothesis that the concept of RSeS can be exploited to design effective lead structures 
for potential application in Medicine. The list of RSeS starts from elemental selenium 
nanoparticles and goes on to include several complex redox modulating organo-
selenium compounds. The compounds employed as part of this thesis range in their 
chemical complexity from simple inorganic selenium salts, such as sodium selenite 
(Na2SeO3) and sodium selenate (Na2SeO4) to highly reactive organic selenazolinium 
salts and from simple aromatic selenocyanates to multi-component hybrid molecules.  
4.1. Selenium Nanoparticles: The Spell of Red Moon 
Selenium (elemental) nanoparticles represent the very first and foremost member in the list of 
RSeS which are very simple in nature yet extremely effective in biological systems. Although 
elemental (red) selenium is generally insoluble in aqueous solutions, nanotechnology could be 
employed to produce rather stable nano-suspensions of selenium nanoparticles. With the 
recent developments in the field of nanotechnology, such particles can be generated 
astoundingly easily and in remarkable yields and reasonable amounts following three different 
procedures: a) naturally (biologically) by employing certain bacteria, b) physically by 
applying shear forces with the help of grinding mills and high pressure homogenization, and 
c) by precise chemical reduction of inorganic salts of selenium, such as SeO3
2-
. Intriguingly, 
in all above mentioned procedures, the red allotropic form of elemental selenium 
predominantly prevails as compared to the grey form [70,107]. Besides the significance of 
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being ‘‘nano’’ in nature (and size), these particles provide additional benefits such as, they a) 
apparently foster the bioavailability of elemental selenium, b) can be generated not only 
naturally but also as part of green synthesis by a variety of conventional bacteria, including 
Staphylococcus carnosus (S. carnosus), Staphylococcus aureus (S. aureus) Bacillus 
oryziterrae (B. oryziterrae), Klebsiella pneumoniae (K. pneumoniae) and Lactobacillus brevis 
(L. brevis), c) are frequently coated with proteins, and d) serve as excellent multifunctional 
agents effective against plethora of targets, such as microorganisms and cancer cell lines 
[70,108-110].  
Whilst the phenomenon of biologically produced particles of elemental selenium has been 
established during the last couple of decades, the characteristics, features and potential 
applications of such pure elemental selenium-based particles have very recently gained the 
attention of research and Industry. It is interesting to note that when certain bacteria, such as 
the ones mentioned above, are treated with excessive amounts of selenite, detoxification by 
simple ‘‘bioreduction’’ of inorganic selenite to elemental selenium is rendered inefficient. 
The target bacteria are eventually forced to employ the more aggressive approach of 
producing solid particles which, in turn, induce severe physical stress and trigger intense 
widespread mechanical damages within the target bacteria. The prokaryotic bacteria are 
generally incapable of digesting, dissolving, facilitating or excreting such very hard and solid 
particles themselves. Under these circumstances those microorganisms become “vulnerable”  
and immediately develop sensitivity towards antibiotics or even the particles which ultimately 
results in the death of these bacteria. Hence this very simple approach of nurturing the 
notorious methicillin-resistant strains of S. aureus on inorganic salts of selenium i.e. selenite 
and consequent generation of red elemental selenium nanoparticles can be utilized to re-
sensitize these nasty, pathogenic and highly resistant members of ESKAPE family. In 
contrast, eukaryotic mammalian cells generally circumvent this rather dangerous ‘‘zero 
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oxidation state’’ of elemental selenium by reducing it to H2Se and a variety of consequent 
products which, subsequently culminate either in selenium-based amino acids or are expelled 
in the form of excretory products, such as methyl-2-acetamido-2-deoxy-1-seleno-β-d-
galactopyranoside, dimethyl selenide and trimethyl selenonium salts [66,111-113].  
These results undeniably raise the concerns regarding the inherent toxic nature of these 
particles and this notion is sturdily authenticated by the presence of a particular protein 
coating around the particle, distinctive of the relevant bacteria employed for the generation of 
particles [114,115]. Interestingly, these biologically produced environment friendly, green in 
nature and red in colour, selenium particles exhibit excellent antimicrobial activities against a 
plethora of microorganisms, including Gram-Positive bacteria (Staphylococcus carnosus), 
Gram-negative bacteria (Escherichia coli), yeast (Saccharomyces cerevisiae) and also 
multicellular round worms representative of agricultural pests (Steinernema feltiae). 
Moreover, Lactobacillus species were employed to produce similar particles in milk 
supplemented with selenite, and the resulting dairy product was employed as a fortified 
cocktail for promoting health [110,116]. 
Nonetheless, there are some remaining mysteries which need to be resolved. The first, and 
perhaps the most compelling query is related to the mode of action of these particles, for 
instance, whether these particles follow pro-oxidant or antioxidant pathways. It can be 
proposed that these particles follow the footsteps of elemental selenium which serves as 
antioxidant at sub-nutritional and pro-oxidant at supra-nutritional doses [117]. Secondly, it 
remains to be demonstrated whether the selenium component, or the protein coating, is mainly 
involved in their most prominent biological activities. A comparative study reveals that 
biogenic SeNPs exhibited more antimicrobial activity compared to synthetic SeNPs which 
divulges the notion that proteins associated with the SeNPs contribute to the overall biological 
activities of biogenic SeNPs [118]. From a more pragmatic perspective, what would be the 
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practical applications of such particles? Pharmaceutical preparations in the form of anti-
infective creams or lotions for dermal application provide a vast ground for the possible 
applications for such particles. Moreover, from the perspective of application in agriculture, 
selenium nanoparticles may be employed as (a) ‘‘green’’ phyto-protectants efficiently 
shielding against the attacks of certain pests, molds and other pathogens, (b) an essential trace 
element enhancing the strength and intrinsic resistance of crops against pathogenic attacks 
and, finally, (c) nutritional enrichment of crops with selenium which adds special value to the 
long-lasting food chain and subsequently to consumers i.e. most frequently human beings.  
4.2. Selenocyanates: Inspired by Nature  
Selenocyanates are selenium analogues of naturally occurring thio and isothiocynates 
in cruciferous vegetables [119]. Isothiocyanates and thiocyanates belong to the group of 
Reactive Sulfur Species (RSS), which are generally very reactive and electrophilic in nature. 
Naturally occurring (iso)thiocyanates are prominent for their interactions with the cysteine 
residues of proteins and enzymes of the cellular thiolstat [87]. Such an extensive “oxidative 
onslaught” in target microorganisms often causes a substantial increase in toxicity, even in 
otherwise resistant organisms [87,119-122]. A significant increase in chemical and biological 
(re)activity is observed for the selenium analogues of naturally occurring RSS. The idea of 
isosteric replacement of sulfur with selenium in naturally occurring RSS is quite fascinating 
from the perspective of small molecule drug design [123]. Intriguingly, literature reveals that 
isosteric replacement of sulfur with selenium in aromatic isothiocyanate significantly 
increases the sensitivity and activity of compounds towards thiols in proteins and thereby 
inducing higher levels of apoptosis [124].  
Selenocyanates represent a very interesting class of organo-selenium compounds like its iso 
neighbour (i.e. isoselenocyanates) which is highly reactive. One of the most interesting 
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feature of selenocyanates is their ability to serve as multifunctional agent as these compounds 
are not only active on their own, they are also frequently metabolized to a wide range of 
several other RSeS, such as selenols, diselenides and seleninic acids [98,99,125-127]. 
Selenocyanates are not “outlandish” and - either directly or as metabolites - perform several 
important roles in Biology [128]. Nonetheless, there is a lack of detailed investigations. 
In line with other organo-selenium compounds and RSeS, selenocyanates, prepared as 
a part of this thesis, demonstrated excellent antimicrobial, nematicidal and cytotoxic 
activities. The detailed studies disseminated in the previous sections stipulated 
innovative insights into the chemistry, pharmacokinetic behaviour and biological 
activities of these compounds, which may be valuable in the hunt for novel 
antimicrobial agents. Interestingly, most of the compounds employed, especially 
benzyl selenocyanate (1), demonstrated considerable activity against both Gram-
positive and Gram-negative bacteria at significantly lower concentrations (i.e. 0.76 µg 
mL
-1
). The antibacterial activity of benzyl selenocyanate (1) was comparable to or even 
higher than the ones of conventional antibiotics, such as piperacillin, oxacillin and 
ampicillin. The activity of some other compounds even surpassed the antibacterial 
effect of oxacillin, especially against the most dangerous, aggressive and drug-resistant 
pathogenic strains of S. aureus. Likewise, a significant activity was observed against 
rather challenging Gram-negative bacteria, such as A. baumannii and P. aeruginosa. In 
order to broaden the scope of antimicrobial activity, the compounds were evaluated for 
antifungal activity revealing certain levels of selectivity; some selenocyanates 
exhibited a relatively high fungicidal activity against infectious C. albicans and a low 
activity against baker’s yeast S. cerevisiae which is good news for medical and 
culinary applications.  
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Detailed investigations are required to explicate the underlying mechanism(s) of action 
and to improve the chemical and biological activity, and hence, selectivity of 
selenocyanates. It can be primarily postulated that selenocyanates and their respective 
metabolites, i.e. selenides, diselenides and seleninic acids randomly interact with the 
cysteine proteins and enzymes and, thereby, disturb the cellular thiolstat of the target 
organism [87]. Such an arbitrary interaction is rather common within chalcogen redox 
chemistry and may also illuminate the capability of such electrophilic compounds to 
overpower different modes and mechanisms of resistance in the target organisms.  
The scope of natural RSeS extends from simple elemental selenium nanoparticles 
produced naturally from microorganisms to the plethora of synthetic compounds 
inspired by nature, such as seleno-flavonoids, seleno-resveratrol and seleno-
coumarines [129-133]. Selenocyanates and isoselenocyanates could now be considered 
as fascinating addition to the “carte du jour” of RSeS which are capable of breaching 
the mechanism(s) of resistance in harmful pathogens [134]. These compounds may 
spice up the future hunt for effective antibiotics inspired by natural chemistry and 
biology. 
4.3. Selenazolinium salts: Simple yet effective 
Moving from the selenium analogues of natural products to pure synthetic organo-selenium 
compounds, we come across a huge number of selenium-containing organic molecules. 
Despite an ever growing scientific interest in the development of organo-selenium 
compounds, which has resulted in such a massive number of selenium-containing compounds, 
there is only one selenium agent which has successfully crossed the milestone and entered 
clinical trials i.e. ebselen [27,135]. Ebselen chemically belongs to the class of selenazoles and 
has been reported to serve as multifunctional agent due to the broad range of applications 
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associated with ebselen ranging from simple detoxification to its efficacy in treatment of 
various diseases associated with vital organs, such as the nervous system and cardiovascular 
system [28]. Ebselen, therefore, serves as an excellent lead structure from the perspective of 
drug design and one of the many journeys for the hunt of ebselen-like selenium compounds 
paves the way towards the development of selenazolinium salts [73].  
In line with other RSeS, the innovative class of selenazolinium salts demonstrated outstanding 
in vitro antibacterial activity against notorious ESKAPE pathogens. The compounds exhibited 
excellent potential against eleven strains of S. aureus and especially against the multidrug-
resistant Staphylococcus aureus (MRSA) and vancomycin-intermediate Staphylococcus 
aureus (VISA) clinical isolates. Interestingly, and in contrast to ebselen, the selenazolinium 
salts demonstrated a significant antibacterial activity against Gram-negative ESKAPE 
bacteria, such as K. pneumoniae, A. baumannii, P. aeruginosa, and E. coli. Furthermore, 
safety of the compounds with regard to pharmaceutical applications was confirmed employing 
Ames mutagenicity assays. The difference in the rate and extent of (re)activity of different 
compounds towards specific or general cellular target(s) may explain the difference in the 
antimicrobial activities of ebselen and the selenazolinium salts. Generally, as mentioned 
earlier (section 4.1.), RSeS interact with the thiol groups of the cysteine residues of proteins 
and interrupt the cellular thiolstat by disturbing the intracellular levels of thiols and 
glutathione in the target microorganisms [87]. It would be interesting to investigate if these 
interactions are stoichiometric, or — as may also be expected from the activities even at lower 
concentrations — catalytic with respect to intracellular levels of ROS and thiols. It may also 
be postulated that the selenazolinium salts interact more than once with cellular proteins and 
enzymes, and that the most active species are not the salts themselves, and rather a highly 
reactive seleno-sulfide intermediate generated as a consequence of interactions of these salts 
with GSH. 
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Detailed future investigations focussed on exploring the mechanisms of actions may reveal 
further differences between ebselen, which is most frequently considered as an “antioxidant” 
promoting cell survival by decreasing intracellular ROS levels together with GSH, and these 
unique RSeS, which, owing to their relatively high(er) (re)activity, apparently interact with 
the thiol residues of cysteine proteins rather randomly and therefore modulate the level of 
GSH and also interfere with proteins and enzymes. In view of such remarkable properties, it 
can be concluded that the selenazolinium scaffold provides a prominent chemical moiety in 
the pursuit of novel selenium-containing drug molecules  
4.4. Selenium based Multifunctional Redox catalysts  
Oxidatively stressed cells are generally characterised by elevated levels of intracellular ROS 
when compared to normal cells [136]. In normal healthy cells, the intracellular levels of ROS 
are generally lower and any unusual upsurge in the levels of ROS even in low micromolar 
concentrations is indicative of diseases associated with OS [137,138]. This difference of 
intracellular ROS levels could be exploited to design agents with sensor and effector 
characteristics to serve as redox catalysts for selective targeting of oxidatively stressed cells 
[139-141]. Within the realm of redox catalysts, some members of RSeS, selenides and 
diselenides for instance, serve as excellent catalytic agents which can mimic the most 
prominent family of redox enzymes, such as glutathione peroxidase (GPx). Moreover, these 
selenium-based agents are not only extremely selective for their substrate(s) i.e. ROS, they are 
also highly effective, i.e. catalytic at low concentrations [139-141]. 
Several studies reinforce the notion of utilizing redox catalysts as drug molecules capable of 
sensing a specific (bio)chemical cellular ‘‘signature’’ as a substrate and subsequently 
unleashing their potential antioxidant or cytotoxic activity in response. Amongst these redox 
catalysts, selenium-based compounds which respond to a wide spectrum of ROS are of 
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particular significance, since these agents are able to sense the complicated intracellular redox 
status of the cell during OS. Another promising approach to tackle such a complex 
intracellular redox situation involves the introduction of multiple redox centres in the same 
molecule enabling these agents to interact with the broad range of intracellular ROS. The 
gamut of redox centres is not confined to the chalcogen family alone, it also contains 
benzoquinones, naphthoquinones, lapachones and some other ‘‘redox rogues’’ [142-144]. 
Then again, chalcogens enjoy special status in the list of redox catalysts as other ‘‘redox 
rogues’’ generally interact with cellular components and oxidize different targets, for 
example, membranes, metalloproteins and a variety of redox systems. Chalcogen-based 
catalysts, in contrast, demonstrate significant selectivity for thiols, thereby interacting 
specifically with the cellular thiolstat of the target organism by activating highly specific thiol 
related signalling or cascade pathways [87]. 
Several of these chalcogen-based multifunctional hybrid molecules comprising of two redox 
centres, i.e. chalcogen and redox modulating quinone were designed, synthesized and 
biologically evaluated by the research group of Prof. Jacob. Interestingly, these compounds 
served as excellent redox catalysts and initial studies revealed that the compounds were able 
to selectively target oxidatively stressed cells. The mechanistic studies subsequently unveiled 
the mode of action of these compounds and it was observed that these catalysts increase the 
level of OS in the target cells. These multifunctional redox catalysts were evaluated against a 
broad spectrum of microorganisms to extend the scope of applications of these compounds 
from cytotoxicity to antimicrobial activities. In line with the previous studies, the compounds 
exhibited excellent antimicrobial activities at concentrations even lower than established 
conventional antibiotics.  
The concept of introducing multiple redox centres is not limited to the seleno-quinones but 
also includes compounds in which selenium is combined with other redox centres, such as 
Discussion 
__________________________________________________________________________________ 
84 
 
lapachones and products of Click Chemistry. From the perspective of medicinal chemistry 
and drug design, these compounds usher in an innovative generation of RSeS which provides 
plenty of impetus for an astounding synthetic chemistry especially in this era of selenium 
chemistry. 
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5. Conclusions 
The present study revolves around demonstrating the synthesis and biological 
significance of selected organo-selenium compounds to emphasise the implication of 
the emerging concept of Reactive Selenium Species (RSeS). Indeed, the results 
obtained as part of this thesis confirm the significance of this concept and its 
applications in various fields, such as synthetic and medicinal chemistry, redox 
biology, pharmacology, biochemistry and medicine. The concept of RSeS is currently 
in its primitive form and is expected to manifest itself fully in the near future. This is, 
of course, possible not only by following the footsteps of Reactive Sulfur Species 
(RSS) due to the inherent analogy of sulfur with selenium, but may also move a few 
steps further due to the highly nucleophilic nature of selenium when compared to 
sulfur.  
Although there is growing interest in the hunt for the hidden treasures of naturally 
occurring selenium-based organo-molecules, the expedition is challenged by certain 
factors, such as lower or even trace amounts of such species, crude detection methods, 
limitation of the available analytical techniques or merely due to the presence of these 
species in areas which no “fortune hunter” has reached so far. At the same time, there 
is also an increasing interest in the synthesis of organo-selenium compounds for 
potential applications in Medicine.  
The scope of RSeS extends from simple elemental selenium nanoparticles (SeNPs) to 
rather complex multifunctional selenium-based redox catalysts equipped with sensor / 
effector properties capable of targeting cells with redox imbalances selectively and 
effectively. Irrespective of the method of generation (i.e. chemically, biologically or 
mechanically), SeNPs have been employed for a broad range of biological and medical 
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applications as antimicrobial, antiviral, antioxidant, immuno-modulatory, 
cytoprotective and cytotoxic agents [118,145-147]. The range of applications for 
SeNPs is not restricted to medicine only, yet it also involves nutrition and agriculture 
[70,148-150]. Naturally or biologically produced SeNPs, which are generated by 
employing certain microorganisms, are generally coated with proteins which may not 
only interfere with the biological activities of these particles, they may also serve as 
stabilizers, and as surfactants to avoid agglomeration of these particles, which is 
important from the perspective of dosage form development. The nature, type, 
biochemical composition and biological implications of these coating proteins provide 
further grounds for detailed investigations. 
Moving from naturally produced SeNPs to the selenium analogues of natural products, 
selenocyanates represent a class of very simple and often overlooked species. 
Selenocyanates are highly effective selenium-based organic compounds which are 
closely related to the isothiocyanates found in cruciferous species. Selenocyanates 
synthesized as a part of this thesis demonstrated excellent antimicrobial, nematicidal 
and cytotoxic activities especially against the resistant strains. Moreover, the 
compounds successfully endured various assays concerning the safety and stability. 
Detailed investigations are required to unveil the underlying mode of action of these 
highly reactive RSeS. The interesting biological effects of these organo-selenium 
compounds could be explained by interactions of these species themselves or their 
metabolites, such as diselenides or seleninic acids, or combinations of both, with the 
components of the cellular thiostat of the target (micro)organisms. There are several 
other examples where selenium analogues of certain natural products have been 
prepared and biologically evaluated, such as resveratrol, coumarins and flavonoids. 
Efficiency of these RSeS against a broad spectrum of biological targets confirms the 
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significance of the notion of RSeS and provides opportunities for the addition of 
selenium-based spices, such as red pepper, cumins or curcuma to the existing menu of 
RSeS.  
Apart from selenium analogues of natural products, the growing interest expands to 
include the synthesis of organo-selenium compounds from the perspectives of pure 
synthetic and medicinal chemistry. This has already resulted in a plethora of such 
agents and some of them, such as ebselen, have been successful enough to enter 
clinical trials. Ebselen, therefore, serves as an excellent lead structure for the design 
and synthesis of selenium-based agents. Selenazolinium salts represent one of the most 
prominent class of compounds with ebselen-like chemical structures. These members 
of RSeS are characterized by the presence of selenazole ring and a positive charge on 
the selenium attributing more nucleophilic character to these compounds, also when 
compared to ebselen. Selenazolinium salts demonstrated excellent antimicrobial 
activity especially against the resistant strains of bacteria. As expected, significant 
differences remain in some of the biological activities of selenzolinium salts and 
ebselen, which beg the question of scientific exploration in greater detail employing 
certain tools of intracellular diagnostics. An overall remarkable biological activity 
associated with selenazolinium salts clearly indicates that selenazolinium motif, in the 
near future, could be employed in the design of efficient RSeS. Moreover, these RSeS 
may also be considered for the next steps of drug development. A thorough and 
comprehensive understanding of the modes and mechanisms of action related to 
selenazolinium salts is required to expand the scope of applications of these agents. 
Furthermore, the Se–N moiety may be more tuned and “sharpened” to increase the 
(bio)chemical (re)activity and selectivity of these compounds. 
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Another interesting approach for enhancing the selectivity and biological activity of the 
organo-selenium compounds involves the introduction of another redox centre, besides 
selenium, in the same molecules. The last couple of decades has witnessed a significant 
interest in the design, synthesis and biological evaluation of catalytic RSeS, especially the 
ones equipped with ‘‘sensor/effector’’ features. Synthetic medicinal chemistry of organo-
selenium compounds continues to move forward and provides advances towards the synthesis 
of multifunctional redox catalysts, which were primarily synthesized following very simple 
and rather straightforward nucleophilic displacement reactions of diphenyl diselenide with 
halogenated quinones. Other sophisticated approaches involve the coupling of two or three 
redox modulating components in linear and/or sequential fashion, multi-component reactions, 
such as Passerini and Ugi reactions, and last but not the least, Click reactions to merge the 
most appropriate redox motifs to produce RSeS with desired characteristics. 
The interest in the emerging concept of RSeS is fuelled by novel discoveries which 
unveil the significant and facet-rich medicinal and biological applications of these 
species especially against targets which are difficult to tackle, such as multi-drug 
resistant bacteria and cancer cells. 
Although the concept of RSeS is rather vague now, it provides guidance and direction  
for both the current and future “pedigree” of selenium researchers and scientists or 
even for some “Selenists”. Moreover, the concept of RSeS also paves the way for 
research on the very special “red carpet” of selenium-based naturally occurring and 
chemically synthesized, organic and inorganic compounds with significant biological 
relevance. Finally, the natural or naturally inspired RSeS constitute a very peculiar 
niche of redox biology, whilst the synthetic RSeS furnish leads for unique and novel 
drug molecules, yet the pursuit kind of lingers to eternity and the scientific toil should 
never stop. 
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Aromatic selenocyanates as a unique class of non-mutagenic 
antimicrobial selenium compounds with pronounced activity 
against multidrug resistant ESKAPE bacteria 
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General procedure for the synthesis of 
selenocyanates 
Selenocyantes were synthesized using the general protocol 
described by Wheeler and Merriam with some modifications.
1
 
According to the procedure, alkyl halides (10-20 mmol) were 
treated with KSeCN (12-25 mmols) in the presence of ethanol (10-
20 mL). The reaction mixture was refluxed for 6 h and the progress 
of the reaction was monitored periodically by Thin Layer 
Chromatography (TLC). After the completion of the reaction, the 
inorganic salt was separated by filtration and the filtrate was 
heated with charcoal. The reaction mixture was filtered hot and the 
filtrate was left for cooling. On cooling, the solution yielded crystals 
which were separated by filtration. TLC was performed to evaluate 
the purity of the compound. Once purified, the samples were 
analysed using Mass Spectroscopy (MS) and Nuclear Magnetic 
Resonance (NMR) for structural confirmations as well as purity. 
Synthesis and chemical characteristics of compounds 1, 3-7 and 10-
12 have been described before and our values are in agreement 
with the reported values 
2-4
. 
Synthesis of Benzyl selenocyanate (1) 
Benzyl bromide (1.71 g, 10 mmol), KSeCN (1.73 g. 12 mmol) and 
ethanol (10 mL) were employed. The compound (1) was obtained as 
light crystals after purification by recrystallization with ethanol. 
Yield 72.5 % (1.43 g, 7.25 mmol). m.p.= 71-72 °C, TLC Rf (DCM, 100 
%): 0.64, 
1
H NMR (DMSO-d6, ppm): δ 7.36(m, 3H, 3C-H), 7.35 (m, 
2H, 2 C-H), 4.30 (t, J=9.15 Hz, 2H, CH2). 
13
C NMR (DMSO-d6, ppm): δ 
138.79, 129.32 (2C), 129.04 (2C), 128.26,105.36(Se-CN), 33.08. LC–
MS: purity 100 %, tR = 5.52, (ESI) m/z: calculated for C8H7NSe 
[M+H]
+
. 91.05, found: 91.00. 
Syn thes i s  o f  3 -Me thy lben zy l  se le no cya na te  (3 )  
3-Methylbenzyl chloride (2.812 g , 20 mmol) , KSeCN (3.6 g. 25 
mmol) and ethanol (20 mL) were employed. The compound (3) was 
obtained as light crystals after purification by recrystallization with 
ethanol. Yield 83.5 % (3.51 g, 16.7 mmol). m.p.= 55.5-56.5 °C, TLC 
Rf (DCM, 100 %): 0.65, 
1
H NMR (DMSO-d6, ppm): δ 7.23(m, 1H, CH), 
7.16 (m, 2H, 2CH), 7.11 (m, 1H, CH), 4.26 (t, J=9.10 Hz, 2H, CH2), 
3.24 (s, 3H, CH3). 
13
C NMR (DMSO-d6, ppm): δ 138.60, 138.15, 
129.82 (2C), 128.93 (2C), 126.42, 105.34 (Se-CN), 33.09, 21.42. LC–
MS: purity 98.57 %, tR = 6.24, (ESI) m/z: calculated for C9H9NSe 
[M+H]
+
: 105.07, found: 105.02. 
Syn thes i s  of  4 - tr i f lu oro methy lbenzy l  se le no cya n ate  
(4 )  
4-Trifluoromethylbenzyl bromide (4.73 g, 20 mmol), KSeCN (3.6 g. 
25 mmol) and ethanol (20 mL) were employed. The compound (4) 
was obtained as light crystals after purification by recrystallization 
with ethanol. Yield 81.75% (4.32 g, 16.35 mmol). m.p.= 54-55 °C, 
TLC Rf (DCM, 100%): 0.94, 
1
H NMR (DMSO-d6, ppm): δ 7.64 (d, 
J=8.21 Hz, 2H, 2 C-H), 7.42(d, J=8.21 Hz, 2H, 2 C-H), 4.02 (t, J=8.21 
Hz, 2H, CH2). 
13
C NMR (DMSO-d6, ppm): δ 144.67, 130.06, 128.07, 
127.64, 125.56, 110.00, 30.87. LC–MS: purity 95.66 %, tR = 9.82, 
(ESI) m/z: calculated for C9H6F3NSe [M+H]
+
: 159.04, found: 159.04. 
Syn thes i s  o f  4 - f lu oro ben z y l  se le no cya na te  (5 )  
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4-Fluorobenzyl chloride (2.89 g, 20 mmol), KSeCN (3.6 g. 25 mmol) 
and ethanol (20 mL) were employed. The compound (5) was 
obtained as light crystals after purification by recrystallization with 
ethanol. Yield 83.45% (3.57 3g, 16.69 mmol). m.p.= 64-65 °C, TLC 
Rf (PE:EA; 4:1) : 0.60, 
1
H NMR (DMSO-d6, ppm): δ 7.25 (m, 2H, 2 
CH), 7.12 (m, 2H, 2 C-H), 3.92 (t, J=7.62 Hz, 2H, CH2). 
13
C NMR 
(DMSO-d6, ppm): δ 163.30, 160.07, 135.94, 131.29, 115.43, 30.93. 
LC–MS: purity 96.30 %, tR = 9.06, (ESI) m/z: calculated for C8H6FNSe 
[M+H]
+
: 109.05, found: 109.00. 
Syn thes i s  o f  2 - f lu oro ben z y l  se le no cya na te  (6 )  
2-Fluorobenzyl chloride (2.892g, 20 mmol), KSeCN (3.6g. 25 mmol) 
and ethanol (20 mL) were employed. The compound (6) was 
obtained as light crystals after purification by recrystallization. Yield 
75.45% (3.231g, 15.09 mmol). m.p.= 48-50 °C, TLC Rf (DCM, 100%): 
0.53, 
1
H NMR (DMSO-d6, ppm): δ 7.44 (m, 1H, 1 CH), 7.36 (m, 1H, 1 
CH), 7.21(m, 2H, 2 CH), 4.33 (t, J=9.14 Hz, 2H, CH2). 
13
C NMR 
(DMSO-d6, ppm): δ 161.13, 159.16, 131.56, 130.16, 124.51, 115.59, 
104.39 (Se-CN), 25.37. LC–MS: purity 96.30 %, tR = 9.06, (ESI) m/z: 
calculated for C8H6FNSe [M+H]
+
: 109.05, found: 109.00. 
Syn thes i s  o f  4 - c h lor ob enz y l  se le no cya na te  (7 )  
4-Chlorobenzyl bromide (2.673g, 16.6 mmol), KSeCN (2.8 g, 19.4 
mmol) and ethanol (20 mL) were employed. The compound (7) was 
obtained as light crystals after purification by recrystallization with 
ethanol. Yield 85.24% (3.263g, 14.15 mmol). m.p.= 58-59 °C, TLC Rf 
(DCM, 100%): 0.75, 
1
H NMR (DMSO-d6, ppm): δ 7.34 (d, J=8.79 Hz, 
2H, 2 CH), 7.25 (d, J=8.21 Hz, 2H, 2 CH), 3.93 (t def., 2H, CH2). 
13
C 
NMR (DMSO-d6, ppm): δ 138.78, 131.96, 131.15, 128.72, 30.87. LC–
MS: purity 99.35 %, tR = 9.99, (ESI) m/z: calculated for C8H6ClNSe 
[M+H]
+
: 125.02, found: 125.02. 
Syn thes i s  o f  4 - br om obe nz y l  se le no cya na te  (10 )  
4-Bromobenzyl bromide (5 g, 20 mmol), KSeCN (3.6 g. 25 mmol) 
and ethanol (20 mL) were employed. The compound (10) was 
obtained as light crystals after purification by recrystallization with 
ethanol. Yield 62.15% (3.417 g, 12.43 mmol). m.p.= 102-103 °C, 
TLC Rf (DCM, 100%): 0.86, 
1
H NMR (DMSO-d6, ppm): δ 7.47 (d, 
J=8.21 Hz, 2H, CH), 7.18 (d, J=8.21 Hz, 2H, CH), 3.91 (t, J=7.62 Hz , 
2H, CH2). 
13
C NMR (DMSO-d6, ppm): δ 139.18, 131.65, 120.46, 
30.93. LC–MS: purity 100 %, tR = 10.23, (ESI) m/z: calculated for 
C8H6BrNSe [M+H]
+
: 168.97, found: 168.94. 
Syn thes i s  o f  4 - n itr obe nzy l  se le n ocy an ate  (1 1)  
4-Nitrobenzyl chloride (3.432 g, 20 mmol), KSeCN (3.6 g. 25 mmol) 
and ethanol (20 mL) were employed. The compound (11) was 
obtained as light crystals after purification by recrystallization with 
ethanol. Yield 72% (3.471g, 14.4 mmol). m.p.= 99-100 °C, TLC Rf 
(DCM, 100%): 0.50, 
1
H NMR (DMSO-d6, ppm): δ 8.21 (m, 2H, CH), 
7.63 (m, 2H, CH), 4.39 (t def, 2H, CH2). 
13
C NMR (DMSO-d6, ppm): δ 
146.97, 130.57, 124.26, 105.25, 31.61. LC–MS: purity 97.77%, tR = 
5.30, (ESI) m/z: calculated for C8H6N3O2Se[M+H]
+
: 136.04, found: 
135.98. 
Syn thes i s  of  2 - (se len o cy ana to met hy l )  na p hth a len e  
(12 )  
2- Chloromethyl naphthalene (2.51g, 14.2 mmol), KSeCN (2.6 g. 18 
mmol) and ethanol (14 mL) were employed. The compound (12) 
was obtained as light crystals after purification by recrystallization 
wit ethanol. The compound was obtained in 81.27 % yield (2.85 g, 
11.54 mmol). m.p.= 119-120 °C, TLC Rf (DCM, 100%): 0.77, 
1
H 
NMR (DMSO-d6, ppm): δ 7.92 (m, 4H, CH), 7.53 (m, 3H, CH), 4.49 (t, 
J=9.14 Hz, 2H, CH2). 
13
C NMR (DMSO-d6, ppm): δ 135.76, 132.65, 
132.36, 128.40, 127.76, 127.60, 127.38, 126.89, 126.49, 126.33, 
104.94 (SeCN), 33.12. LC–MS: purity 97.56%, tR = 6.73, (ESI) m/z: 
calculated for C12H9NSe [M+H]
+
: 141.07, found: 141.03 
Crystallographic Studies 
The crystallographic studies have been performed to provide 
evidence about the stability of the arylmethylselenocyanates when 
exposed to different solvents and temperature, considering a 
potential reactivity of the selenocyanate moiety. The molecular 
structures and atomic-numbering schemes of 1 and 12 are 
presented and described in main article (Figure 2). Parameters of 
intermolecular C-H.···N interactions for 1 and 12 are shown in Table 
S1. The geometries of the methyleneselenocyanate groups in both 
compounds differ slightly. The responsible angles have values C1-
Se1-C2 = 95.2° and 95.5°, Se1-C2-C3 = 113.7° and 114.3°, C1-Se1-C2-
C3 = −62.4° and -66.5°, Se1-C2-C3-C4 = 98.6° and 98.8°, whereas the 
torsion angle N1-C1-Se1-C2 exhibits a significant difference of 
−164.4° and 67.3° for compound 1 and 12, respectively. 
Methylselenocyanate fragments were also searched for in the 
Cambridge Structural Database (CSD, Version 5.37), which resulted 
in five crystal structures, in one case two independent molecules.
5
 
In these crystal structures, the values of torsion angles N1-C1-Se1-
C2 were 66.8°, −170.9°, −139.5°, 29.4°, −131.7° and −173.1°. 
 
Table S1. Parameters of intermolecular C-H.···N interactions for 1 
and 12. 
Cpd D-H.···A  
H···A 
(Å) 
D. ···A (Å) 
D-H···A 
(°) 
Symmetry 
Codes 
1 
C2-
H2A···N1 
2.59 3.559(3) 174 −x, −y, −z 
 
C2-
H2B···N1 
2.73 3.328(3) 119 x + 1, y, z 
 
C6-
H6···N1 
2.84 3.513(3) 128 
−x, y − 1/2,  
−z + 1/2 
12 
C2-
H2A···N1 
2.58 3.487(2) 155 
x + 1/2, −y + 1, 
−z 
 
C2-
H2B···N1 
2.76 3.333(1) 118 x, y − 1, z 
 
C8-
H8···N1 
2.75 3.520(2) 141 
x − 1/2,  
y − 1/2, z − 1/2 
 
Ames fluctuation assay 
Compounds 1, 2 and 13 were also non-mutagenic at the higher 
concentration of 10 µM which was employed in most of the assays. 
Only compound 4, at the higher concentration (10 µM), exhibited 
an increased binomial B–value (B = 1.0), which may point towards a 
probable mutagenic potential. The mutagenicity of this derivative is 
rather ambiguous, as the value of the second parameter indicative 
of mutagenicity (MI = 1.75) was still below the threshold of 2.0, and 
substantially lower compared to the MI value for the mutagenic 
reference NQNO with a MI = 6.91 calculated at a concentration of 
0.5 µM (Figure 1). 
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Figure 1. Results of the Ames liquid microtitre test indicative of 
mutagenic potential; DMSO (1 % in growth medium)-negative 
control, ebselen (reference compound) at the concentration 1 µM 
and 10 µM, NQNO (4-nitroquinoline-N-oxide, benchmark mutagenic 
agent) at concentration 0.5 µM; 1, 2, 4 and 13 — selenocyanates at 
concentrations 1 µM and 10 µM, ----- baseline defining the 
mutagenicity threshold (significant mutagenicity above this line). 
 
In Vitro PAMPA Permeability. 
The results calculated for compound 13 may be ambiguous due to 
the instability of the compound in phosphate buffered saline (pH 
7.4), as around 50 % decomposition was determined by controlled 
LC-MS analysis (data not shown). 
Table 2. ADMET properties of the most active compounds (1, 2, 4, 
13). 
 
ADME–Tox Properties 
Compounds 
Mutagenic  
Potential 
PAMPA- 
Permeability 
MI  
(1 µM) 
B 
MI  
(10 
µM) 
B Kp (cm s-1) 
1 1.15 0.74 1.20 0.81 2.69 × 10
-6
 
2 1.04 0.56 0.87 0.28 3.17 × 10
-6
 
4 1.25 0.87 1.75 1.0 2.57 × 10
-6
 
13 1.47 0.96 0.82 0.14 2.25 × 10
-6
 
Ebselen 0.69 0.26 0.80 0.46 nd 
Caffeine nd nd Nd nd 3.61 × 10
-6
 
Norfloxacin nd nd Nd nd 0.95 × 10
-6
 
Ebselen - selenium reference compound in Ames test. Reference 
compounds in PAMPA: high-permeable drug, caffeine; low-
permeable drug, norfloxacin. MI - mutagenic index (the quotient of 
the number of revertant colonies induced in a test sample and the 
number of revertants in a negative control). B - Binomial B value, nd 
not determined; Kp - permeability coefficient. 
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13 C NMRs of synthesized compounds 
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7.2. Supplementary material for Publication 2: Selenazolinium Salts 
as "Small Molecule Catalysts" with High Potency against ESKAPE 
Bacterial Pathogens. 
Supplementary 
 
* Particularly potent antibacterial activities (MIC < 5 μg/ml) are underlined. 
3.3. Evaluation of ROS formation 
To analyze the effect of the selenazolinium salts tested on intracellular oxidative stress production in 
S. aureus DCHFA assay was performed. For this purpose, the impact of the most active compounds 
which were identified in the previous studies (the compounds 1 and 6) and ebselen on ROS release 
was determined in the reference S. aureus ATCC 25923 strain and the clinical isolate MRSA HEMSA 5 
(Figure S1-S3) 
 
 
 
Table S1. Details of MIC values of the compounds 1-8 and ebselen against Gram-negative bacteria. 
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Figure S1. Generation of intracellular ROS in the reference S. aureus ATCC 25923 strain (a) 
and the clinical MRSA HEMSA 5 isolate (b) upon exposure to the different concentrations of 
the compound 1. 2, 2′-azobis (2-amidinopropane) dihydrochloride (AAPH) was included as 
a positive control in the assay. The level of oxidative stress was detected by the use of 
fluorogenic dye 2ʹ, 7ʹ-dichlorodihydrofluorescein diacetate (DCHFA) which in the 
presence of cellular esterases and ROS is converted to highly fluorescent 2', 7'-
dichlorofluorescein (DCFA). Values represent means with standard deviation (SD) bars from 
at least four repeats. Statistical significances were calculated using a one-way ANOVA 
followed by Bonferroni’s multiple comparison test (Figure S1 a, b: p > 0.05). 
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Figure S2. Generation of intracellular ROS in the reference S. aureus ATCC 25923 strain (a) 
and the clinical MRSA HEMSA 5 isolate (b) upon exposure to the different concentrations of 
compound 6. For further details refer to the Figure S1. 
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Figure S3. Generation of intracellular ROS in the reference S. aureus ATCC 25923 strain (a) 
and the clinical MRSA HEMSA 5 isolate (b) upon exposure to the different concentrations of 
ebselen. For further details, refer to the Figure S1. 
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